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Abstract 
The objective of this study was to investigate the transmission mode of Human 
herpesvirus type eight (HHV8) in Hong Kong. For this purpose, three studies 
(seroprevalence, cervical DNA prevalence, and genotype distribution) were 
conducted in various Hong Kong populations. 
HHV8 seroprevalence study was carried out in the general population and three 
risk groups. Antibodies against HHV8 latent antigens and antibodies against lytic 
antigens were detected by body cavity-based lymphoma cell line (BCBL-1) derived 
antigens using the immunofluorescence technique. The overall HHV8 seroprevalence 
among the general population was 9.4% (94/1000). Female individuals had a 
significantly higher seropositivity than males (11.6% versus 7.2%, P = 0.002, odds 
ratio = 1.65, 95% CI = 1.06-2.58). Among the three risk groups, 7.5% (5/67) of 
human immunodeficiency virus-negative intravenous drug users, 15.8% (6/38) of 
human immunodeficiency virus-positive individuals without Kaposi's sarcoma, and 
10.2% (5/49) of transfusion-dependent patients had HHV8 antibodies. HHV8 
seroprevalence was not significantly higher in these risk groups in comparison with 
the sex- and age-matched reference groups. The results indicate that HHV8 infection 
exists at a low prevalence in Hong Kong. Our findings that primary infection occurs 
after puberty suggest that sexual transmission is likely in Hong Kong people. In 
addition, the presence of HHV8 infection in a small proportion of children suggested 
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that non-sexual transmission of HHV8 exists in Hong Kong. 
The HHV8 DNA prevalence in cervical scrapes from 193 general female 
population and 202 female sexually transmitted disease clinic attendees were 
determined by a nested PGR targeting the HHV8 ORF 26. The overall positive rate 
was 6.7% (13/193) among the general female population, and 5.5% (11/202) among 
the sexually transmitted disease clinic attendees. The sexually transmitted disease 
clinic attendees did not show a higher HHV8 DNA prevalence compared to the 
general female population. Although a certain proportion of HHV8 DNA is observed 
in both the general female population and the sexually transmitted disease clinic 
attendees, the similar DNA prevalence in these populations suggests that HHV8 
might not be efficiently transmitted by genital tract secretion. 
HHV8 nucleotide sequence variation was determined by sequencing a 120-bp 
fragment of HHV8 ORF 26. Altogether, nine isolates from cervical samples and four 
from Kaposi's sarcoma tissues were studied. Over the 120-bp fragment, six 
nucleotide positions exhibited mutations, and three of them were nonsynonymous. 
Based on a previously described genotyping system, six cervical isolates were 
classified into subtype A, three cervical isolates were classified into subtype B, and 
the other four Kaposi's sarcoma isolates were classified into subtype B or subtype C. 
The phylogenetic comparison with HHV8 isolates derived from other populations 
suggests that most HHV8 cervical isolates derived from Hong Kong belong to the 
same branch of the phylogenetic tree. The correlation between tissue tropism and the 
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1.1 Discovery of HHV8 
In 1872, Kaposi's sarcoma was first described as a rare skin tumor, which was 
mainly prevalent in elderly Mediterranean males (O'Leary, Kennedy and Mcgee 
1997). From the 1980s, a tremendous increase in the incidence of Kaposi's sarcoma 
had been reported among homosexual and biosexual men infected with human 
immunodeficiency virus (HIV) (Isovich et al. 2000). Although HIV is considered an 
important cofactor for the development of Kaposi's sarcoma, epidemiologic studies 
suggest that another infectious agent is also involved (Offermann 1996). Direct virus 
isolation from Kaposi's sarcoma has been attempted to identify an infectious agent 
responsible for Kaposi's sarcoma, and several candidate agents including 
cytomegalovirus and papillomavirus were suspected to play an etiologic role. But no 
likely infectious agent was directly cultured from Kaposi's sarcoma lesions (Sarid, 
Olsen and Moore 1999). 
Given the failure of virus culture method, molecular techniques were used to 
identify the nucleic acids from the putative agent. In 1994, Chang et al. reported that 
they used representational difference analysis to identify and characterise unique 
DNA sequences in Kaposi's sarcoma tissue. With the use of genomic DNA from 
Kaposi's sarcoma lesion that was compared to unaffected DNA from the same patient, 
two subgenomic BamUl fragments of DNA, designated KS330 Bam and KS 631 
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Bam were identified (Chang et al. 1994). These two unique DNA fragments had high 
sequence homology to known herpesviruses, and were used as Southern 
hybridization probes and for generation of polymerase chain reaction (PGR) primers 
leading to identification of the whole sequence. These sequences suggested the 
presence of a new human herpesvirus in Kaposi's sarcoma lesions and the 
herpesvirus was subsequently named as Kaposi's sarcoma-associated herpesvirus 
(KSHV) or human herpesvirus type eight (HHV8) (Sarid, Olsen and Moore 1999). 
1.2 Biology of HHV8 
1.2.1 Morphology 
HHV8 is an enveloped virus. The diameter of envelope ranges from 120 nm to 
150 nm (Said et al 1997). The virion comprises four concentric layers: inner core, 
capsid, tegument and envelope. The inner core contains a large double-stranded 
DNA. The capsid is an icosahedron which consists of 162 hollow capsomers. 
Surrounding the capsid is the amorphous structure termed tegument. The tegument is 
in turn sheathed in a lipid envelope bilayer, which is derived from the nuclear 
membrane (Said et al. 1997). 
1.2.2 Classification 
Phylogenetic analysis using both single gene and combined gene sets 
demonstrates that HHV8 belongs to gamma II herpesvirus and is the first member of 
this genus known to infect human (Moore et al. 1996) (Neipel, Albrecht and 
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Fleckenstein 1998). Among the gamma herpesvirus, HHV8 is closer to herpesvirus 
saimiri that infects animals rather than the Epstein-Barr virus (EBV), which is the 
prototype lymphocryptovirus and is ubiquitous in human (Heller and Kieff 1981). 
1.2.3 Cell culture 
A variety of Kaposi's sarcoma tissues have been used as sources for establishing 
HHV8-positive cell lines, but none was successful (Offermann 1996). In 1995, BC-1 
and BC-2 cell lines were established from body cavity-based lymphomas (BCBL). 
These cell lines that retain the HHV8 sequences have been used to further 
characterise HHV8 viral genome. Most BCBL cell lines are coinfected with EBV, for 
example HBL-6, BC-1, BC-2, and BCBL-2 cell lines, whereas the BCBL-1 cell line 
distinguishes itself from others by harbouring HHV8 but not EBV. Under normal 
growth conditions, HHV8 displays a highly restricted pattern of gene expression in 
BCBL cell line (Renne, Zhong and Hermdier 1994). Some scientists reported that 
lytic viral replication could be induced under the treatment with the phorbol ester 
tetradecanoyl acetate. The lytic viral replication is characterised by transcription of 
extensive regions of the viral genome, synthesis of viral DNA, and the accumulation 
of enveloped virions in the cells and medium (Zhong, Wang and Herndier 1996). 
1.2.4 Latent and lytic life cycle 
Gamma herpesviruses characteristically establish latent infection in lymphoid 
cells. During latency, the gamma herpesvirus expresses a very limited gene 
programme and primarily relies on cellular replication machinery for genomic 
replication and repair. Latent HHV8 infection in cell culture can shift spontaneously 
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into lytic replication cycle (Miller et al. 1997). In addition, latent HHV8 could be 
induced to a lytic phase replication cycle by the phorbol ester tetradecanoyl acetate. 
When transcription switches from a quiescent latent phase to the production of whole 
virion, the full complement of viral genes is expressed and the whole HHV8 virion is 
produced. It is referred to as the "lytic phase" of the virus life cycle since it is 
postulated to lead invariably to cell lysis and death (Sarid, Olsen and Moore 1999). 
1.2.5 Genome organisation 
The large HHV8 DNA molecule is located predominantly in the nucleus of the 
infected cells (Cesarman, Moore and Rao 1995). The HHV8 genome is 165 kilobase 
long and encodes conserved structural and DNA replication proteins that are 
characteristic for members of the herpesvirus family. The HHV8 genome has a long 
unique region flanked with terminal repeat units consisting of multiple 801-bp direct 
repeat units with potential packaging and cleavage sites (Moore and Chang 1998). 
The terminal repeat units region include 35-45 repeats. Although repeats are not 
arrayed uniformly and symmetrically at each end, the total number of repeated DNA 
per genome is relatively fixed (Lagunoff and Ganem 1997). The 137.5-kilobase long 
unique region is divided into highly conserved and nonconserved gene blocks (Russo, 
Bohezky and Chien 1996) (Moore and Chang 1998). The highly conserved gene 
blocks include seven blocks of conserved herpesvirus genes, named gene block I to 
VII. These gene blocks contain conserved herpesvirus genes coding for viral 
structural proteins and enzymes involved in viral DNA replication, nucleotide 
synthesis, and thymidylate synthase (Russo, Bohezky and Chien 1996). Within the 
non-conserved gene blocks (Block A-Block H) are genes that are either homological 
to other gamma herpesviruses or are unique to HHV8. In gene block A, B, C, D, and 
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E, most genes are unique to HHV8. The nomenclature for individual viral genes 
unique to HHV8 have been designed with a "K" prefix and numbered sequentially 
while the genes homological to other gamma herpesviruses are named after 
corresponding genes from the prototypic gamma herpesvirus saimiri (ORFs 4-75) 
(Russo, Bohezky and Chien 1996). The gene block B also contains several genes 
with homologies to mammalian proteins (Schulz 1998). 
1.2.6 Strain variability 
HHV8 genome is well conserved within coding regions. Less than 0.1% base 
pair variation has been observed between the BC-1 and a 210-kilobase fragment 
isolated from a Kaposi's sarcoma lesion (Moore et al.l996) ( Russo, Bohenzky and 
Chien 1996). Based on combined sequence analysis of loci at ORF 25, ORF 26, ORF 
75, and an upstream of ORF 75 sequences, three distinct HHV8 strains have been 
identified and a total of 38 variable positions have been observed over the total 
2500-bp segments (Zong, Metroka and Reize 1997). 
The ORF26 HHV8 block represents a well-conserved virion protein coding 
region displaying 60% amino acid homology among the HHV8 and other gamma 
herpesviruses. There are nine polymorphic nucleotide positions over the limited 
distance of the 233-bp standard ORF 26 fragment between the KSl and KS2 primers 
originally described by Chang et al. in 1994 (Chang et al. 1994). Four positions are 
considered as key strain designators, resulting in three major subtypes, referred to as 
A, B, and C. More than 90% of HHV8 isolates from Kaposi's sarcoma and BCBL 
samples from United States patients with acquired immunodeficiency syndrome 
(AIDS) can be classified into either A or B subtypes. The majority of the classical 
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Mediterranean isolates fell into subtype A while isolates from Africa represented 
subtypes C and scattered diverged variants of subtype B (Zong, Metroka and Reize 
1997). 
ORF 75 represents a relatively poorly conserved region with less than 30% 
amino acid homology among HHV8 and other gamma herpesviruses. A 515-bp 
fragment from ORF 75 has been analysed. Eight positions are considered as key 
strain designators in this 515-bp region. The variability seen among HHV8 isolates 
within ORF 75 appears small. All the samples falling into subtype A in ORF 26 gene 
analysis were found identical within the ORF 75 block. The overall nucleotide 
variability was 1.6% over 500-bp for ORF 75. The lack of intrastrain variation was 
apparent (Zong, Metroka and Reize 1997) 
HHV8 has a highly variable ORF K1 gene located at the left end of its genome. 
The 870-bp KI gene encodes a 289 amino acid polypeptide that has features of a 
membrane-bound and largely extracellular immunoglobulin receptor-like protein 
(Zong, Ciufo and Alcendor 1999). The high-level variability leads to the discovery of 
four major subtypes (A, B, C, and D) and 13 distinct variants of HHV8 (Meng et al. 
1999). A novel subtype E was identified from Brazilian American by Biggar et al. in 
2000 (Biggar, Whitly and Marshall 2000). Different nomenclature systems for HHV8 
genotyping have been employed by different investigators. Zong and his colleagues 
used a classification system based on subtypes A, B, C, and D, whereas others used 
classification system based on genotypes I，IV, II and III accordingly (Meng et al. 
1999) (Zong, Ciufo and Alcendor 1999) (Lacoste et al. 2000). 
Based on sequencing of fragments from ORF Kl , molecular epidemiological 
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studies have been carried out to study the genotype distribution. The K1 nucleotide 
sequences of samples from United States, German, Russia, and Japan mainly 
clustered into subtype I/A and subtype II/C (Lacoste et al. 2000) (Meng, Sata and 
Stamey 2001). The strains from Australia mainly represent subtype III/D and strains 
from Africa mainly represent subtype lY/B (Meng et al. 1999) (Zong, Ciufo and 
Alcendor 1999). ORF K1 DNA sequences from the BCl and BCBL-1 cell lines all 
represent subtype A (Lagunoff and Ganem 1997). 
The K1 gene protein patterns have been further divided into 13 variants based 
on amino acid difference or on the presence of common distinctive in-frame 
deletions within the variable regions. Additional numeric description (eg., Al to A5, 
CI to C5, and Dl or D2) has been used to assign these variants. Among different 
strains of subtype A ORF K1 proteins, up to 5 to 8% amino acid difference has been 
reported while 14 to 15% amino acid difference has been found between two major 
branches of subtype C ORF K1 proteins. It has been reported that most 
AIDS-associated Kaposi's sarcoma samples from United States patients are Al , A4, 
or C3 variants. C2 and C3 subtypes are disseminated among classic Kapsoi's 
sarcoma cases throughout Europe and Asia including Israel, Sicily, Scandinavia, 
South Korea, and Taiwan (Zong, Ciufo and Alcendor 1999). 
1.3 Disease association of HHV8 
1.3.1 Kaposi's sarcoma 
Kaposi's sarcoma has a strong relationship with HHV8. Firstly, HHV8 DNA 
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can be detected in over 95% of Kaposi's sarcoma lesions from a wide variety of 
geographic settings, but it is rarely found in control tissues from patients without 
Kaposi's sarcoma. Examination of Kaposi's sarcoma biopsies shows that both spindle 
cells and endothelial cells of nodular cutaneous Kaposi's sarcoma lesion harbour 
HHV8 (Offermann 1996). The odds ratio for detection of HHV8 DNA in Kaposi's 
sarcoma tissue is over 100, suggesting an extraordinarily strong correlation between 
HHV8 and Kaposi's sarcoma (Sarid, Olsen and Moore 1999). This, combined with 
the high load of herpesvirus-like DNA sequence in affected tissue than in unaffected 
tissue from very different populations are strong arguments for a role in the 
pathogenesis of Kapos's sarcoma (Huang et al. 1995). Secondly, the prevalence of 
HHV8 is significantly increased in groups at risk for Kaposi's sarcoma. Lastly, 
seroconversion precedes the onset of Kaposi's sarcoma in ADDS patients (Neipel and 
Fleckenstein 1999). 
Kaposi's sarcoma can be classified into four distinct types based on clinical and 
epidemiological differences: the classic Kaposi's sarcoma, the endemic Kaposi's 
sarcoma, the iatrogenic immimosuppression-associated Kaposi's sarcoma and the 
AIDS-associated Kaposi's sarcoma (Porter, Alberti and Kuman 1998). 
The classic Kaposi's sarcoma was first described in 1872 (Kaposi 1872). It 
occurs predominantly in elderly Mediterranean descent. The incidence rate of classic 
Kaposi's sarcoma varies in European countries. The lowest incidence is in England 
and Wales. In North Europe, the incidence is higher than in England, but lower than 
in Italy. The highest incidence rates in Europe are in two Mediterranean Italian 
Islands: Sardinia and Sicily, where classic Kaposi's sarcoma occurs more frequently 
in individual older than 50 years (Isovich et al. 2000). 
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The endemic Kaposi's sarcoma has a high incidence rate in central Africa. 
Childhood Kaposi's sarcoma is not rare in African populations, and often takes a 
rapid progression towards mortality (Ziegler and Katongole-Mbidde 1996). 
The third subtype of Kaposi's sarcoma is post-transplant Kaposi's sarcoma 
which is highly related to iatrogenically induced immunosupression (Sarid, Olsen 
and Moore 1999). 
The fourth subtype of Kaposi's sarcoma is AIDS-associated Kaposi's sarcoma, 
which was first described in the early 1980s in the United States. Fifty per cent of 
HHV8 and HIV dual infected homosexual individuals in Northern Europe and 
United States developed AIDS-associated Kaposi's sarcoma within 5-10 years 
(Renwick, Halaby and Weverling 1998). Thus, infection with HIV is an important 
co-factor in the development of Kaposi's sarcoma. Moreover, Kaposi's sarcoma is 
more common in HIV-positive homosexual men comparing to the relatively lower 
incidence in HIV-positive haemophiliacs, transfusion recipients, and intravenous 
drug users (Porter, Albert! and Kuman 1998). 
1.3.2 Other associated diseases 
BCBL has been found to have strong relationship with HHV8. HHV8 could be 
found in all forms of BCBL (Sarid, Olsen and Moore 1999). In addition to BCBL, 
HHV8 also plays a contributory role in multicentric Castleman's disease, a rare form 
of B-cell lymphoma that occurs most frequently in AIDS patients (Schulz 2000). 
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Evidence of HHV8 association with a broader range of human diseases 
including multiple myeloma and Bowen's disease awaits confirmation (Sarid, Olsen 
and Moore 1999). 
1.4 Tropism of HHV8 
Kaposi's sarcoma lesions contain a complex mixture of cell types. The spindle 
cells represent the most predominant and characteristic cell type. Besides, the 
endothelial cells of nodular cutaneous Kaposi's sarcoma lesion also harbour HHV8. 
These findings all support that Kaposi's sarcoma cells are of endothelial origin and 
infection with HHV8 is important in the pathogenesis of the disease (Offermann 
1996). HHV8 DNA sequence could be found in the majority cases of Kaposi's 
sarcoma. With the use of PCR, HHV8 DNA sequences have been found in affected 
tissues from 91%-100% of AIDS-associated Kaposi's sarcoma patients, 94%-100% 
of classic Kaposi's sarcoma individuals, 70% of endemic Kaposi's sarcoma 
individuals from Africa and 100% of iatrogenic Kaposi's sarcoma patients (Moore 
and Chang 1995) (Huang et al. 1995) (Engelbrecht et al. 1997). By in situ 
hybridisation for viral RNA and in situ PCR for viral DNA, HHV8 viral RNA and 
DNA have been detected in most Kaposi's sarcoma lesions (Engelbrecht et al. 1997) 
(Li et al. 1996) (Boshoff et al. 1995) (Zhong, Wang and Herndier 1996). 
Although HHV8 DNA sequences have been exclusively found in endothelial 
cells, including their spindle variants in Kaposi's sarcoma lesion, several other cell 
types have been found to harbour HHV8 both in vivo and in vitro. Some reported that 
HHV8 DNA sequences were obtained from peripheral blood mononuclear cells of 
HIV-infected individuals with or without Kaposi's sarcoma (Collandre et al. 1995). 
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HHV8 also exhibits a broader spectrum of peripheral blood cell tropism in patients 
with classical and AIDS-associated Kaposi's sarcoma. The viral DNA is not only 
detectable in CD 19+ cells, but also in T cells and monocytes. Furthermore, CD34+ 
cells in peripheral blood of Kaposi's sarcoma patients have also been reported to be 
predominantly harboring HHV8 (Henry et al. 1999) (Blasig et al. 1997). Although 
some reported that HHV8 DNA sequences were not detectable in normal endothelial 
cells from Kaposi's sarcoma patients, the viral genomes were occasionally found 
from unaffected tissue of classic Kaposi's sarcoma patients by PCR (Li et al. 1996) 
(Boshoff et al. 1995). Some scientists also reported the presence of HHV8 DNA in 
skin and visceral samples from unaffected tissues of Kaposi's sarcoma patients, 
suggesting the dissemination of HHV8 in many organs of the target individuals (Noel 
et al. 1996). 
HHV8 DNA sequences have been detected in a high percentage of HHV8-
associated diseases, such as BCBL and multicentric Castleman's disease (Cesarman 
et al. 1995) (Cesarman and Knowles 1995) (Soulier et al. 1995). HHV8 DNA has 
been also detected in primary central nervous system lymphomas from patients with 
or without ADDS (Corboy, Gaii and Kleinschmidt-Demasters 1998). Additional study 
shows the presence of HHV8 DNA sequences in the bone marrow dendritic cells of 
patients with multiple myeloma (Rettig et al. 1997), although no association between 
HHV8 and multiple myeloma has been confirmed (Marcelin et al. 1997) (MacKenzie 
et al. 1997). 
In general, B lymphocyte has been considered as a target cell for HHV8 as 
described by most studies (Engelbrecht et al. 1997) (Li et al. 1996) (Boshoff et al. 
1995) (Zhong, Wang and Herndier 1996). The latent viral state with nuclear episome 
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in the Kaposi's sarcoma biopsies and BCBL cells has been documented in many 
studies (Russo, Bohezky and Chien 1996) (Decker et al. 1996). The expression of 
lytic HHV8 genes has also been documented in monocytes and peripheral blood 
mononuclear cells (Decker et al. 1996) (Blasig et al. 1997). Further studies in 
determining a "latent-lytic loop" among blood lymphocytes and the cells of the 
Kaposi's sarcoma lesion in various states of immune function should be carried out 
(Dictor 1997). 
1.5 Epidemiology of HHV8 
1.5.1 Geographic distribution 
Unlike other human gamma herpesviruses, HHV8 is not a ubiquitous infection 
in the general population (Louise, Chatlynne and Ablashi 1999). The prevalence of 
HHV8 varies greatly in different geographic regions (Schulz 2000). 
The seroprevalence among the general populations ranges from 0% to 40% 
worldwide with a low seroprevalence in Northern America and Northern Europe, and 
highest seroprevalecne in Africa, an endemic area of Kaposi's sarcoma. Although 
seroprevlence varies because of variable methods used in detection of viral 
antibodies, there is uniform conclusion that the prevalence of HHV8 is low in the 
general population and the HHV8 infection is more prevalent in countries where 
classic and endemic Kaposi's sarcoma occurs (Whitby, Barrozi and Boshoff 1998). 
In the United States where Kaposi's sarcoma occurrence is very low, HHV8 
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infection appears rare in the general population. HHV8 seroprevalence among US 
blood donors ranges from 0% to 3% in detection of antibodies to latency-associated 
nuclear antigen (LANA) using immunofluorescence assay (IFA) (Gao, Kingsley and 
Li 1996) (Rezza, Lennette and Giulani 1998). In detection of antibodies against lytic 
antigens, the seropositivity ranges from 5% to 20% according to different methods 
applied (Lennette, Blackbourne and Levy 1996) (Enbom, Sheldon and Lennette 
2000) (Simpson, Schulz and Whitby 1996). 
A low seroprevalence is also observed in Northern Europe. In United Kingdom, 
the seropositivity of HHV8 antibodies to latent antigen by IFA is 3% (Louise, 
Chatlynne and Ablashi 1999). In Sweden, seroprevalence among blood donors 
ranges from 0.6% to 6% for HHV8 antibodies against latent antigens (Enbom, 
Sheldon and Lennette 2000). The prevalence of HHV8 infection is found to be much 
higher in Southern Europe than in Northern Europe. In Italy, HHV8 seroprevalence 
among Italian blood donors appears to be higher than that among blood donors from 
United Kingdom and Sweden. Seroprevalence rate among Italian blood donors for 
antibodies to HHV8 LANA is 2.1%, but for antibodies against lytic antigen is 27.7% 
(Rezza, Lennette and Giulani 1998) (Ablashi, Chatlynne and Cooper 1999). Even in 
the same country, the distribution of HHV8 infection is not uniform. In Northern and 
Central Italy, the seroprevalence is 7% for the antibodies against LANA. However, 
the seroprevalence is 25% in the blood donors from Southern Italy using the same 
antibody detection method (Whitby, Barrozi and Boshoff 1998). This geographic 
distribution of HHV8 seroprevalence in Southern and Northern Italy corresponds 
with the fact that Southern Italy, a Mediterranean region, has a high incidence of 
classic Kaposi's sarcoma. 
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The highest seroprevalence rate is in Africa, where Kaposi's sarcoma has a 
highest incidence. With the use of IFA, antibodies against lytic antigen were detected 
in 77% of the general populations in Uganda (Lennette, Blackbourne and Levy 1996). 
In the general population in Gambia, which has highest incidence of Kaposi's 
sarcoma in the world, the positivity for HHV8 latent and lytic antigens was 29% and 
84%, respectively (Lennette, Blackbourne and Levy 1996). 
Little data about the HHV8 seroprevalence have been collected in Asia. 
Antibodies against lytic antigen by IFA have been reported in 11% of healthy 
individuals in Taiwan (Huang et al. 2000). With the use of Enzyme-linked 
immunosorbent assay for HHV8 lytic antibodies, HHV8 infection has been found in 
4% of participants from India, 4% of participants from Thailand, 4.4% of participants 
from Malaysia, and 3.8% of participants from Sri Lanka (Ablashi, Chatlynne and 
Cooper 1999). This restricted distribution of HHV8 in the Southeast Asian general 
populations correlates with the fact that relatively low incidence of cases of classic 
Kaposi's sarcoma or AlDS-associated Kaposi's sarcoma has been reported in Asia. 
1.5.2 Age distribution 
In United States, study on the age distribution of HHV8 showed that primary 
HHV8 infection occurred in adults rather than in children and teenagers, suggesting a 
possibility of sexual transmission of HHV8 in the United States (Andrew, Shizuko 
and Pamela 1997). 
In Africa, a Kaposi's sarcoma endemic area, HHV8 infection takes place 
progressively during childhood. In Cameroon, the seroprevalence level reaches 48% 
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by 15 years of age (Antoine, Philippe and Moniqiie 1999). Among Ugandan children 
and adolescences, 42.5% have antibodies to HHV8 ORF 65 protein, 33% have 
antibodies to LANA, and 52% have at least one of the two antibodies (Mayama, 
Cuevas and Sheldon 1998). The finding that primary infection of HHV8 mainly 
occurs before puberty suggests that sexually transmission is not a likely explanation 
for the high seroprevalence in Kaposi's sarcoma endemic areas. 
Although few investigations have been carried out in Southeast Asian countries, 
a sero-survey from Taiwan showed a similar pattern of HHV8 age distribution as in 
United States. The study showed that 3% to 4% children before 10 years old had 
antibodies against HHV8 lytic antigens (Huang et al. 2000). The highest infection 
rate was observed among young adults between 20 and 40 years old (Huang et al. 
2000). Nearly 20% of adults from years 31 to 40 were infected with HHV8 (Huang 
et al. 2000). This observation is compatible with a sexual route of transmission for 
HHV8，which is similar to the transmission mode in United States. 
1.5.3 HIV-infected individuals without Kaposi's sarcoma 
111 general, the prevalence of HHV8 antibodies against lytic antigens is higher 
among HIV-infected patients than among HIV-negative individuals (Rezza, Lennette 
and Giulani 1998). In the United States, by a whole virus enzyme-linked 
immunosorbent assay, HHV8 infection has been found in 28% of HIV-infected 
patients without Kaposi's sarcoma (Ablashi, Chatlynne and Cooper 1999). Kedes et 
al. also reported that 30% of HIV-positive blood donors from United States had 
antibodies to LANA (Kedes, Operskalski and Biisch 1996). Furthermore, among 
HIV-infected individuals from United States and Northern Europe, HHV8 antibodies 
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are significantly more frequently in homosexual men than in other risk groups for 
HIV transmission ( Schulz 1998). Some also reported that antibodies against HHV8 
latent antigens were found in only 5% of HIV-positive intravenous drug users and 
detected among HIV-positive haemophilia participants (Simpson, Schulz and Whitby 
1996). The fact that HIV-positive homosexual men have a significantly higher 
HHV8 infection rate than other HIV-positive patients was also supported by reports 
from United States, where 83.4% of HIV-positive homosexual men, 55% 
HIV-positive intravenous drug users and only 25% HIV-positive heterosexual 
contacts had antibodies to HHV8 lytic antigens (Rezza, Lennette and Giulan 1998). 
By LANA antibody tests, this uneven distribution pattern among different 
HIV-positive populations has also been observed (Rezza, Lennette and Giulan 1998). 
In Italy, there is a similar observation that HHV8 prevalence is higher among HIV 
homosexual men than in other HIV risk groups (Calabro, Sheldon and Favero 1998) 
(Whitby, Barrozi and Boshoff 1998). The different distribution of HHV8 infection 
among HIV-infected Kaposi's sarcoma risk groups correlates with the findings that 
the incidence of Kaposi's sarcoma is high among HIV-infected homosexual men and 
is rare in HIV-infected haemophilia patients or in the HIV-infected intravenous drug 
users (Beral, Peterman and Berkelman 1990) (Peterman, Jaffe and Beral 1993). 
Some studies revealed a strong association of HIV infection with HHV8 
seropositivity in United States and Europe, whereas the sero-surveys from Southeast 
Asia show that HHV8 seroprevalence is nearly the same between the general 
populations and HIV population. It has been found that only 2% of HIV-positive 
Kaposi's sarcoma-negative participants from India and 11 % of HIV-positive Kaposi's 
sarcoma-negative participants from Thailand are positive by whole virus 
enzyme-linked immunosorbent assay (Louise, Chatlynne and Ablashi 1999). 
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1.5.4 Bone marrow transplant and blood transfusion recipients 
Some reported that previously HHV8 seronegative transplant patients 
seroconverted after transplantation (Enbom, Sheldon and Lennette 2000). This, 
combined with the fact that HHV8 DNA is also found in bone marrow raise the 
possibility that bone marrow transplant patients are at risk for parenteral viral 
transmission (Blasig et al. 1997) (Said, Rettig and Heppner 1997). However, others 
reported that seroconversion was not found more common in patients who received 
HHV8-positive graft than those received HHV8-negative graft, and no Kaposi's 
sarcoma was observed after seroconversion (Rosenzwajg, Fery and Bons 1999). 
Whether bone marrow transplant is a risk factor for HHV8 infection remains to be 
determined. 
Because HHV8 virus is detectable in the peripheral blood mononuclear cells, 
this raises the possibility that cellular components in blood transfusion may transmit 
HHV8. However, no Kaposi's sarcoma cases have been developed in the at-risk 
blood recipients who are immunodepressed later at their lives. The failure to detect 
HHV8 in these blood transfusion patients indicates that HHV8 is not transmitted 
with a high frequency in individuals receiving blood components (Lefrere, Mariotti 
and Girot 1997). Nonetheless, possibility of parenteral transmission of HHV8 via 
blood transfusion can not be excluded. It is possible that transmission occurs but the 
antibody response is below the detection level. More sensitive antibody tests are 
required to obtain a better estimation on the risk of parenteral transmission of HHV8 
(Lefrere, Mariotti and Girot 1997). 
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1.5.5 Sexually transmitted disease clinic attendees 
It has been reported that sexual activity plays a role in the risk of HHV8 
acquisition and antibodies against HHV8 antigens are more frequently detected in 
sexually transmitted diseases clinic attendees (Kedes, Operskalski and Busch 1996). 
It has also been reported that HHV8 infection is associated with a history of several 
sexually transmitted diseases including urethral syphilis, genital or anal-rectal herpes, 
and gonorrhea (Smith, Sabin and Gopal 1999) (Martin, Ganem and Osmond 1998) 
(Rezza, Lennette and Giulani 1998). Particularly, HHV8 seropositivity correlates 
strongly with a history of chlamydial infection or condylomatosis (Tedeschi, 
Caggiari and Silins 2000). Among sexually transmitted disease clinic attendees, 
HHV8 seroprevalence is not higher among those who have homosexual activity than 
those who have heterosexual activities, suggesting that the mode of HHV8 
transmission is not confined to homosexual practice (Simpson, Schulz and Whitby 
1996). 
1.5.6 HIV-negative intravenous drug users 
HIV-negative intravenous drug users have been found to have a higher 
prevalence of HHV8 infection than the general population (Rezza, Lennette and 
Giulani 1998). Martin et al. also reported that there was a significant association 
between HHV8 infection and a history of five years' sharing of needles (Martin, 
Ganem and Osmond 1998). However, the association between sharing of needles and 
HHV8 infection remains to be confirmed because this group may also be more 
promiscuous. Thus, the intravenous drug users do not represent a homogeneous 
population at exclusive parenteral risk of transmission of infectious agents. After 
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adjustment for sexual partners, a conclusion of lack of associations with sharing of 
needles has been reached (Rezza, Lennette and Giulani 1998). 
1.6 Transmission of HHV8 
Epidemiological studies have identified that sexual promiscuity, 
HIV-seropositivity and a history of other sexually transmitted diseases are associated 
with a high seroprevalence for HHV8 (Melbye et al. 1998) (Martin, Ganem and 
Osmond 1998) (O'Brien et al. 1999). Additional evidence supporting a sexual 
transmission route of HHV8 is provided by seroprevalence survey pointing out that 
HHV8 infection is rare in children in the United States and Northern Europe 
(Blauvelt et al. 1997). 
Given the evidence that Kaposi's sarcoma is a sexually transmitted disease in 
United States and Europe, studies have been done on the prevalence of HHV8 DNA 
in semen and in prostate samples in these countries. Conflicting results have been 
obtained. HHV8 DNA was documented in semen from HIV-infected patients with 
Kaposi's sarcoma, but was infrequently found in HIV-infected men without Kaposi's 
sarcoma even in those who were seropositive for HHV8 by IFA for LANA 
antibodies (Gupta et al. 1996) (Howard et al. 1997) (Diamond et al. 1997). HHV8 
does not appear to be frequently detected in semen from healthy populations, neither 
does it appear to be a common infection of prostatic tissue from HHV8-infected 
asymptomatic individuals (Blackbourne and Levy 1997). At present, there is only 
limited evidence for sexual transmission of HHV8 among heterosexuals, although 
some reported the presence of HHV8 DNA in semen from HIV-negative semen 
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donors with the use of nested PGR (Lin et al. 1995). 
In contrast, HHV8 DNA sequences have been detected in 35%-75% of saliva 
samples from HIV-infected patients with Kaposi's sarcoma and in 15% of saliva 
samples from HIV-infected individuals without Kaposi's sarcoma, which suggested 
that saliva may be more important than semen in the sexual transmission of HHV8 
(LaDuca et al. 1998) (Koelle et al. 1997). It has been also reported that the average 
number of HHV8 copies per microgram of sample DNA in saliva and semen sample 
was 33000 and 300’ respectively (LaDuca et al. 1998). The relatively high 
prevalence and copy numbers of HHV8 in saliva than in semen suggest that oral-anal 
contact may be a risk factor for homosexual transmission of HHV8 in developed 
countries (LaDuca et al. 1998) (Vieira et al. 1997). 
With regard to the HHV8 DNA prevalence in Kaposi's sarcoma endemic areas 
where HHV8 infection occurs primarily before puberty in the general populations, 
HHV8 DNA has been detected in 8% of blood samples from HIV-negative Zambian 
infants presenting to hospital with fever (Kasolo, Mpabalwani and Compels 1997). 
HHV8 DNA has also been documented among Uganda infants (Ziegler and 
Katongole-Mbidde 1996). The fact that HHV8 infection is commonly found during 
childhood raises the possibility that HHV8 might be transmitted through non-sexual 
contacts among African children. The presence of HHV8 DNA in nasal secretions 
and saliva from Kaposi's sarcoma patients and HIV-infected individuals may give a 
reason for the primary infection of HHV8 before puberty in Kaposi's sarcoma 
endemic areas ( Blackbourne, Lennette and Giulani 1998). 
The transmission of HHV8 via blood transfusion remains to be determined due 
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to controversial results obtained. Blackbourne and his colleagues reported the 
presence of infectious HHV8 in the peripheral blood mononuclear cells from a blood 
donor in the United States ( Blackbourne et al. 1997). HHV8 DNA has also been 
found in 46% of peripheral blood mononuclear cell samples and 7% of serum 
samples from Kaposi's sarcoma patients (LaDuca et al. 1998). However, the failure 
to detect HHV8 infection in the blood transfusion-dependent patients who had 
received blood components from HHV8-infected blood donors and blood 
transfusion-dependent recipients who got hepatitis C infection through blood 
transfusion suggested that HHV8 is not transmitted with a high frequency in 
individuals receiving blood transfusion (Operskalski, Busch and Mosley 1997) 
(Lefrere, Mariotti and Girot 1997). 
On the contrary, most studies agree that HHV8 plays a role in organ 
transplantation. It has been reported that an HHV8-negative recipient developed 
Kaposi's sarcoma 11 months after receiving organ transplant from an HHV8-positive 
donor (Regamey et al. 1998). Qunibi et al. also reported that patients were infected 
by HHV8 after transplantation (Qunibi et al. 1998). Seroconversion occurring after 
renal transplantation, and Kaposi's sarcoma developing in graft recipients also 
suggests that HHV8 could be transmitted through organ transplantation (Parravicini 
et al. 1997). 
Overall, the available data suggest that different transmission routes exist 
among different populations. As a sexually transmitted agent, HHV8 is transmitted 
through saliva and semen in the homosexual men associated with specific sexual 
behaviour. In the general population from developed countries where primary HHV8 
infection occurs in adults, the acquirement of HHV8 through sexual contact is more 
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likely. Given the lack of large scales HHV8 DNA screening of semen in the general 
population, the evaluation of the role of semen, prostatic fluid, and other body fluid 
in transmission of HHV8 in the general population awaits further studies. In Kaposi's 
sarcoma endemic areas, the high rate of transmission may be due to a widespread 
horizontal transmission, possibly from oral secretions. Although the possibility of 
blood transfusion of HHV8 remains to be determined, the transplantation-related 
transmission has been documented. 
1.7 Methods for HHV8 antibody detection 
Development of reliable, sensitive, and specific serological methods for the 
detection of HHV8 antibodies is critical for a thorough understanding of HHV8 
prevalence and pathogenesis. A variety of serological assays for the detection of 
antibodies against lytic HHV8 antigens and LANA have been developed. 
1.7.1 Antibodies against latent antigens 
LANA is a 222 to 234 kilodalton latent nuclear protein encoded by ORF 73, 
(Rainbow, Piatt and Simpson 1997). Antibodies to LANA can be detected by 
in-house Western blot or in-house IFA (Gao, Kingsley and Li 1996). The sensitivity 
and specificity of LANA-IFA and LANA Western blot are high. In IFA assay, cells 
from EBV-negative BCL cell lines which are not treated with phorbol esters or 
butyrate are used as source of antigen for antibodies against LANA. Antibodies 
against LANA antibodies could be detected by IFA in at least 80% of sera from 
AID-associated Kaposi's sarcoma patients, 85%-94% of sera from classic Kaposi's 
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sarcoma individuals, and 51%-62% blood donors from Uganda (Kedes, Operskalski 
and Busch 1996) (Lennette, Blackbourne and Levy 1996) (Simpson, Schulz and 
Whitby 1996) (Zhu, Wang and Sweat 1999) (Gao, Kingsley and Li. 1996). However, 
it has been found that only 0%-3% United Kingdom, United States, or Swedish blood 
donors have antibodies against HHV8 LANA (Zhu, Wang and Sweat 1999) (Enbom, 
Sheldon and Lennette 2000). 
Western blot assays could also be used to detect antibodies against HHV8 
LANA. It has been reported that Western blot (ORF 73) assay is more sensitive than 
IFA-LANA. Gao et al. reported that all classic Kaposi's sarcoma sera were positive 
by Western blot (Gao, Kingsley and Li 1996). It has also been reported that over 90% 
of sera from AIDS-associated Kaposi's sarcoma and 10% of sera from general 
populations were positive for antibodies against HHV8 LANA with the use of 
Western blot assay (Zhu, Wang and Sweat 1999) (Kedes, Operskalski and Busch 
1996). 
LANA is specific for HHV8, because there is no homologue of ORF 73 in EBV, 
eliminating the possibility of antigen cross-reactivity with this very prevalent gamma 
herpesvirus (Mayama, Cuevas and Sheldon 1998) (Martin, Ganem and Osmond 
1998). However, the sensitivity of the assay in detection of antibodies against HHV8 
LANA is only 80%-95% (Schulz 2000). It is possible that the prevalence of HHV8 
infection has been underestimated when the antibodies against LANA are used in 
measurement of HHV8 infection. 
1.7.2 Antibodies against lytic antigens 
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Treatment of BCBL-derived cell lines with phorbol esters or butyrate could 
induce the expression of HHV8 lytic viral genes (Miller et al. 1997). Serologic 
assays based on lytic (structural) viral proteins are more sensitive comparing to 
anti-latent antibodies detection and could be used to detect antibodies against HHV8 
lytic antigens in almost all serum samples from patients with Kaposi's sarcoma 
(Lennette, Blackbourne and Levy 1996) (Huang et al. 2000) (Martin, Ganem and 
Osmond 1998). Antibodies against HHV8 lytic antigen could be detected by 
in-house IFA in 96% AIDS-associated Kaposi's sarcoma patients, and 100% of 
Kaposi's sarcoma patients from Africa. (Lennette, Blackbourne and Levy 1996) It 
has been reported that, 0%-25% of general populations from United States, Italy, and 
Uganda have antibodies against HHV8 lytic antigens (Lennette, Blackbourne and 
Levy 1996) (Gao, Kingsley and Li 1996) (Miller et al. 1996). 
HHV8 ORF 65 encodes viral capsid protein (Lin et al. 1997). With the use of 
enzyme-linked immunosorbent assay, antibodies to this immunogenic lytic 
cycle-associated protein can be detected in approximately 80% sera from 
AIDS-associated Kaposi's sarcoma patients from United States, United Kingdom, 
and Uganda, 94% of classic Kaposi's sarcoma sera, and 1.7%-5% sera from United 
Kingdom and United States blood donors (Simpson, Schulz and Whitby 1996). 
Using Western blot assay, 95% of AIDS-associated Kaposi's sarcoma sera, and 13% 
of sera from HIV-negative individuals without Kaposi's sarcoma reacted with the 
ORF 65 protein (Zhu, Wang and Sweat 1999). 
1.7.3 Comparison between assays 
Interassay studies showed that most of the assays correlated well when testing 
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sera from AIDS-associated Kaposi's sarcoma patients and classic Kaposi's sarcoma 
patients. However, there existed a relatively poor concordance among available 
serologic assays in assessment of HHV8 infection in general populations (Rabkin, 
Schulz and Whitby 1998). 
In general, the assays for antibodies against lytic antigens are more sensitive 
than those against latent antigens. It has been reported that IFA for antibodies against 
HHV8 lytic antigens is the most sensitive method in detecting HHV8 infection in 
Kaposi's sarcoma patients (Spira et al. 2000). 
Zhu et al. also reported that the lytic antigen-based IFA and lytic antigen-based 
Western blot assays are more sensitive than the ORF 73 Western blot assays and 
latent antigen-based IFA (Zhu, Wang and Sweat 1999). However, it is not clear 
whether the higher sensitivity obtained in lytic antibody test is achieved at the 
expense of higher rate of false positive (Schulz 2000). 
In comparison of these various HHV8 antibody assays, all have been found to 
be effective, but none has been found to be totally satisfactory (Louise, Chatlynne 
and Ablashi 1999). It appears likely that IFA followed by confirmation with the 
Western blot reactions with a panel of latent and lytic antigens or a combination of 
recombinant antigens would provide a reliable, sensitive and specific method for the 
detection ofHHVS antibodies (Zhu, Wang and Sweat 1999) (Schulz 2000). 
1.8 Project design 
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This project consists of three parts of studies. The first part of study focused on 
the seroprevalence of HHV8 in Hong Kong. In order to elucidate the HHV8 
transmission pattern in Hong Kong, four different groups were selected. Age and sex 
distribution of HHV8-positive individuals in the reference group was analysed to 
find out the period during which primary HHV8 infection occurs in Hong Kong 
population. Since HIV-positive individuals have been regarded as a high-risk group 
for HHV8 infection in most studies, this group was also selected for study. 
Intravenous drug users and blood transfusion-dependent patients were included as 
well to investigate the possibility of HHV8 transmission via sharing of needle and 
receipt of blood-transfusion. Serum samples from these populations were tested by 
indirect IFA for antibodies against HHV8 latent and lytic antigens that represent 
exposure of HHV8. 
The second part of this project is to study the prevalence of HHV8 DNA in 
cervical samples in Hong Kong. The objective of this study is to assess whether 
high-risk sexual behavior is a factor of HHV8 transmission among women in Hong 
Kong. For this purpose, sexually transmitted disease clinic attendees and general 
female population who enrolled for cervical cancer screening were selected. HHV8 
DNA was detected with the use of nested PGR, which amplified a fragment of HHV8 
ORF 26 gene. 
The third part of this study focused on the genotype distribution of HHV8 in 
Hong Kong. It has been reported that individuals from diverse geographical locations 
have different HHV8 genotype distribution. Based on the 120-bp HHV8 ORF 26 
fragment amplified from cervical scrapes and Kaposi's sarcoma tissue sample, 
nucleotide sequence variability was examined and genotype distribution pattern was 
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determined. The above studies have been approved by the Ethical Committee of The 
Chinese University of Hong Kong. 
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Chapter Two 
Methods and Materials 
2.1 study I. Seroprevalence of HHV8 in Hong Kong 
2.1.1 Study population 
2.1.1.1 Reference group 
A total of 1000 serum samples collected from patients who attended Prince of 
Wales hospital between 1994 and 2000 were retrieved from Department of 
Microbiology, The Chinese University of Hong Kong. These serum samples were 
tested for viral infection based on clinical indications and were stored at -20°C. This 
reference group was divided into 10 age groups (1-6 months, 7-12 months, 1-5 years, 
6-10 years, 11-15 years, 16-20 years, 21-30 years, 31-40 years, 41-50 years, >50 
years). In each age group, 50 males and 50 females were included. The personal 
identifiers of these patients were deleted, only their names and epidemiological 
information essential for study analyses were retained. 
The reference group was investigated in order to find out the age-specific and 
sex-specific seroprevalence of HHV8 in Hong Kong. This group also served as a 
baseline for comparison with other groups. 
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2.1.1.2 HIV-negative intravenous drug users 
A total of 67 serum samples were collected from intravenous drug users who 
attended the "Substance Abuse Clinic" of the Department of Psychiatry, Prince of 
Wales Hospital. The age and sex distribution of this group is shown in Table 1. 
These samples had been tested negative for HIV antibodies by the Department of 
Microbiology and were kept frozen at -20 °C. Other personal information was 
deleted for consideration of confidentiality. 
Table 1. Age and sex distribution of risk groups for HHV8 seroprevalence study 
Sex Age (yr) 
Risk groups (male/female) Mean/SD Range 
Intravenous drug users 64/3 25.2/8.26 16-50 
Human immunodeficiency virus-infected 33/5 40.3/9.58 25-67 
Transfusion-dependent 24/25 11-5/5.05 2-21 
2.1.1.3 Transfusion-dependent patients 
This group included thalassaemia patients who received blood product every 
four weeks. For clinical purposes, these patients had been tested negative for HIV 
infection at the Department of Microbiology. Their serum samples were kept frozen 
at -20°C. The age and sex distribution is shown in Table 1. 
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2.1.1.4 HIV-positive individuals without Kaposi's sarcoma 
A total of 38 serum samples were received from Queen Elizabeth Hospital. 
These samples had been submitted for HIV testing under clinical indications and all 
had been tested positive for HIV antibodies. This group of patients did not have 
Kaposi's sarcoma at the time of blood sample collection. The age and sex distribution 
is shown in Table 1. 
2.1.2 Source of HHV8 antigens 
Body cavity-based lymphomas cell line (BCBL-1) was used as an antigen source 
for the detection of antibodies against HHV8 latent and lytic antigens. BCBL-1 cell 
line was obtained from the National Institutes of Health in United States. It is a 
suspension cell line established from the body cavity-based lymphoma of a patient 
infected with HIV disease. The cell line is positive for HHV8 but not infected with 
Epstein-Barr virus (EBV). 
Cells were sub-cultured every five days with one in five dilution. For 100 mL 
RPMI working solution, 10 mL heat-inactivated serum, 1 mL of 200 mM glutamine, 
3.6 mL of 4.4% sodium bicarbonate and 85.4 mL RPMI base solution (Invitrogen, 
USA) were added. No antibiotic was used in cell medium. 
2.1.2.1 Preparation of smears for antibodies against HHV8 latent 
antigens 
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BCBL-1 cells were harvested when they were growing in a good condition. Cell 
pellet was obtained by centrifuging the cell suspension at 700g for 15 minutes. 
Afterwards, cell pellet was washed with phosphate buffer saline (PBS) for three 
times to remove remaining medium. BCBL-1 cells were then resuspended and cell 
concentration was adjusted to 1,000,000 per mL. 
Before use, slides were treated with absolute alcohol and were dried in air. Cell 
suspension was thoroughly mixed by pipetting up and down. An aliquot of 15 |LIL of 
cell suspension was smeared evenly within a circle on the slide to obtain a 
monolayer of cells. Overlapping of cell layers was avoided. After smearing, slides 
were dried in room temperature and were placed in a glass-staining dish containing 
4% formalin for 10 minutes. Then, slides were permeated in 0.2% triton for five 
minutes. The slides were dried at room temperature and stored at -20°C . 
2.1.2.2 Preparation of smears for antibodies against HHV8 lytic antigens 
BCBL-1 cell line was latently infected with HHV8. To induce the lytic status of 
HHV8, 10 ng/mL tetradecanoyl phorbol ester acetate (TPA) was added to cell 
suspension. During the initial phase of the study, various duration of TPA treatment 
was tried, and finally 96 hours of TPA treatment was found to be most optimal. 
BCBL-cells were harvested 96 hours after treatment with TPA. Cells were 
washed with PBS for three times. After centrifugation, cell pellet was resuspended 
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with PBS into a concentration of 1,000,000 cells per mL. The slides were prepared as 
described for latent antigens except that acetone was used in fixation. 
2.1.3 Positive and negative controls 
A serum sample obtained from an HIV-positive patient with Kaposi's sarcoma 
was used as positive control. To determine the optimal dilution of the serum, the 
positive control was testd in 1:10, 1:40, 1:80, 1:160, 1:320, 1:640’ 1:1280 and 
1:2560. The detection limit for latent antibodies was found to be 1:640, whereas that 
for lytic antibodies was at 1:1280. Control serum at these dilutions was then used in 
subsequent test runs. PBS was included as a negative control for all test runs. 
2.1.4 Procedures for immunofluorescence assay 
2.1.4.1 Blocking for non-specific binding 
Since the initial trial showed a high non-specific background for most serum 
samples, a blocking step was included in the assay. The blocking solution was made 
by dissolving one gram of skimmed milk powder in 100 mL of PBS. This solution 
was inactivated at 56°C for one hour, and then was aliquoted and stored at -20°C. 
Slides were subjected to blocking by smearing 15 |iL of blocking reagent 
evenly within each circle on the slide. Slides were then put in a humid chamber and 
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were placed at 37°C for 30 minutes. After incubation, slides were washed with PBS 
for three times and dried in air. 
Before the detection of antibodies against HHV8 latent antigens, serum samples 
were diluted 1:50 with blocking reagent by mixing two microlitres of serum sample 
with 98 [iL of blocking reagent. After mixed by pipetting, the sera samples were 
incubated at 37°C incubator for 30 minutes. Positive control at 1:640 dilution was 
also treated with blocking reagent in a similar way. 
Before the detection of antibodies against lytic antigens, serum samples were 
diluted 1:100 with blocking reagent. Two microlitres of serum sample was added to 
198 |iL of blocking reagent. After mixed by pipetting thoroughly, diluted sera were 
incubated at 37 °C for 30 minutes. Positive control was diluted 1:1280 with 
blocking reagent. 
2.1.4.2 Addition of serum samples, FITC-conjugate，and mounting 
procedures 
Fifteen microlitres of 1:50 diluted serum samples for antibodies against HHV8 
latent antigens or 1:100 diluted serum samples for antibodies against lytic antigens 
were added within the circles on the slides. Then, the sera were incubated at 37°C for 
one hour. After incubation, slides were rinsed and washed with PBS for three times. 
Then, 25 |LIL of diluted FITC-conjugate rabbit anti-human antibody was put on each 
circle on slides. After incubation at 3 7 � C for one hour, slides were washed with PBS 
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three times and were dried at room temperature. An appropriate amount of mounting 
medium was applied onto a slide and a coverslip was put down onto the slide. The 
test sera were immediately examined under ultra-violet light (UV) excitation system 
after mounting. 
The dilution of FITC-conjugated rabbit anti-human antibody was initially 
optimised. A serial dilution of FITC-conjugated rabbit anti-human antibody ranging 
from 1:40, 1:60 to 1:80 was tried. A dilution of 1:80 was found to produce the most 
sensitive and specific fluorescent signal. 
2.1.5 Statistical methods 
Chi-square test and Fisher's exact test were used to compare the difference in 
seropositivity between groups. Risk of HHV8 infection was estimated by calculating 
the odds ratio using Epilnfo 2000 (CDC, USA). All statistical analyses were two-
tailed. A P value of less than 0.05 was considered significant. 
2.2 Study 11. Prevalence of HHV8 DNA in cervical scrapes 
2.2.1 Study population 
2.2.1.1 General female population 
To investigate the prevalence of HHV8 DNA in general female population, 193 
well-women who enrolled for routine cervical cancer screening at the Shatin 
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Community Clinic for Prevention of Cervical Cancer were included in this part of 
studies. This well-women group was derived from a female population with 2034 
(97.8%) of them reported to have less than four sexual partners and 46 (2.2%) of 
them experienced sexually transmitted diseases in their lifetime (Chan et al. 2002). 
Their cervical scrapes were collected in 10 mL of PBS. The cell pellet was obtained 
by centrifugation at 700 g for 15 minutes and stored at -20°C. The age distribution of 
this well women group is shown in Table 2. 
2.2.1.2 Sexually transmitted disease clinic attendees 
This group of patients was recruited from the Yau Ma Tei Social Hygiene 
Clinic. Two hundred and two sexually transmitted disease clinic attendees were 
included in this group. In the past one year, 26 (12.87%) of them had five episodes of 
sexually transmitted diseases. Forty-four (21.7%) had less than or equal to three 
episodes of sexually transmitted diseases. The age distribution of this group is shown 
in Table 2. Cervical scrape samples were collected and treated in a similar way as 
described before. 
Table. 2. Age distribution of women for HHV8 DNA prevalence study 
Age (yr) 
Study populations No. Tested Mean/SD Range 
General female population 193 41.8/11.08 19-68 
Sexually transmitted disease clinic attendees 202 34.4/9.70 15-66 
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2.2.2 Preparation of cell lysate 
The method for extraction of DNA from cervical samples was adopted from 
that described before (Ehrlich and Greenberg 1994). Total DNA was extracted from 
cervical scrape samples with the use of digestion solution containing proteinase K. 
Each 100 |iL of digestion solution contained 78 |LIL of 50 mM Tris-HCl (PH 8.5), 1 
mM EDTA, 20 |LIL of Tween 20, and 2 |IL of 20 mg/L proteinase K. 
In each digestion reaction, 50 jiL of digestion solution was mixed with 50 [ih of 
cell suspension. The mixture was incubated at 55°C for one hour. Then, it was heated 
at 95°C for 10 minutes to inactivate proteinase K. After centrifugation, 5 |iL of the 
supernatant of the treated cell lysate were used as inoculum for PCR. All steps for 
extraction of DNA from specimen were carried out in clean area isolated from PCR 
and PCR product handling area. 
2.2.3 PCR amplification for human beta-actin gene 
Before detection of HHV8 DNA, all samples were tested for the housekeeping 
beta-actin gene with the use of beta-actin gene primers, Actin-1 and Actin-2, as 
described by Daibata et al. (Table 3) (Daibata et al. 1998). The quality of extracted 
DNA can be assured by the presence of a 309-bp of PCR product amplified by beta-
actin PCR. Human peripheral blood mononuclear cells were used as positive control 
for beta-actin PCR. The cells were washed with PBS for three times and were heated 
at 90°C for 10 minutes. 
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Table 3. Sequence of oligonucleotide primers for beta-actin gene PCR 
Primer Sequence (5'-3') Genome Size of 
Set Location Amplicon 
Actin-1 5' ACCTTCAACACCCCAGCCATG 3' 449 309 bp 
Actin-2 5' GGCCATCTCTTGCTCGAAGTC 3' 757 
The GenBank accession number of the Homo sapiens actin gene (beta) is NMOOl 101. 
2.2.3.1 Optimisation of beta-actin PCR 
The optimal conditions of beta-actin PCR were determined through titration of 
primer concentrations and annealing temperatures. All other PCR parameters 
including the concentration of dNTP and MgCl2 and pH value were kept constant. 
For the optimisation of annealing temperatures, 53°C, 55�C, and 5TC were tried. A 
series of dilutions of peripheral blood mononuclear cell lysate, with the DNA 
concerntration at 235 ng, 23.5 ng, 2.35 ng, 0.235 ng, 0.0235 ng and 0.00235 ng per 
five micro litres were used as inoculum. 
For the optimisation of primer concentration, 0.125 |IM, 0.25 |LIM to 0.50 |IM 
concerntrations were tried. A series of dilutions of DNA concerntrations at 23.5 ng, 
2.35 ng, 0.235 ng, 0.0235 ng and 0.00235 ng per five microlitres were used as 
inoculum. 
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2.2.3.2 PCR conditions for detection of beta-actin gene 
PGR for beta-actin was performed in a 50 |iL of reaction reagent containing 
Tris-HCl (pH 8.7), (NH4)2S04 ’ KCl, 1.5 mM MgCh, 200 |iM of each dNTP , 0.25 
yiM of Actin-1 primer and Actin-2 primer, and 1.25 Unit of Hotstar Taq DNA 
polymerase (QIAGEN, Germany). Preparation of PCR reagent was carried out in the 
clean cabinet available only for the reagent preparation. DNA samples were mixed 
and microcentrifuged briefly before inoculation. Five microlitres of DNA samples 
was inoculated into the 45 |j,L of PCR master mixture. Thermal cycling was done 
using Applied Biosystem GeneAmp®PCR system 9700. One positive control for 
beta-actin gene was used for every PCR set. Double distilled water was used as 
negative control. A reagent control was also included. PCR was started with initial 
incubation step at 95°C for 15 min for activation of the Hotstart Taq DNA 
polymerase. It was followed by denaturing at 94°C for one minute, annealing at 55°C 
for one minute and extending at 72°C for one minute. After 30 cycles, DNA was 
subjected to an extra extension step that lasted for eight minutes at 72"C. 
2.2.3.3 Detection of PCR product 
The PCR products were detected by agarose gel electrophoresis. Agarose gel 
was prepared by dissolving two grams of agarose powder (FMC Bioproduct, USA) 
in 100 mL of I x TBE buffer. The contents were mixed thoroughly, and were heated 
by microwave oven on high power until bubbles appeared. Afterwards, the solution 
was cooled around 50®C. Then, it was poured into gel cast with upper and lower 
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combs set already. When the gel was set, the upper and lower combs were removed. 
Ten microlitres of PCR product together with two microlitres of loading dye 
(Invitrogen, USA) were loaded into the accommodate wells. OX 174 RF W P J H a e 
III fragments, which are suitable for sizing linear double DNA from 72-1553 bp was 
used as standard DNA mass ladder (Invitrogen , USA). Electrophoresis was carried 
out at 120 volt for 60 minutes. The gel was stained by ethidium bromide (10 
mg/mL)) for 10 minutes and was recorded by ImageMaster Video Documentation 
System (Amershan, USA). A band located at DNA size of 309 bp was considered as 
positive for beta-actin PCR. 
2.2.4 PCR for HHV8 DNA 
HHV8 DNA was detected by nested-PCR targeting a 160-bp fragment of 
HHV8 open reading frame 26 (ORF 26). Outer primers used were KS1 and KS2 
(Table 4), as described by Chang et al. (Chang et al. 1994). This pair of primers can 
amplify a 233-bp DNA fragment from HHV8 ORF 26. The inner primers were NSl 
and NS2 (Table 4), which can be used to amplify a 160-bp fragment internal to the 
KS 1 and KS2 product (Bigoni et al. 1996). 
2.2.4.1 Controls for HHV8 0RF26 PCR 
BCBL-1 cell line harbouring HHV8 genome was used as the positive control. 
The cells were washed and resuspended in PBS. The cell concentration was adjusted 
to 5x105 cells per mL. B95 cell line that is infected by EBV but not HHV8 was used 
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as a negative control for HHV8 PGR. The cells were washed and resuspended with 
PBS to a concentration of 10^  cells per mL. 
Before PGR, the cell suspension was heated at 90°C for 10 min, and then was 
centrifuged. Five microlitres of the supernatant was used as inoculum. 
Table 4. Sequence of oligonucleotide primers for HHV8 ORF 26 gene 
Primer Sequence (5丨-3丨） Genome Size of 
Set Location Amplicon 
Outer PGR KS1 5’ AGCCGAAAGGATTCCACCAT 3' 47586 233 bp 
KS2 5’ TCCGTGTTGTCCACGTCCAG 3' 47818 
Inner PGR NS1 5' ACGGATTTGACCCCGTGTTC 3' 47620 160 bp 
NS2 5' AATGACACATTGGTGGTATA 3' 47779 
Nucleotide position is according to HHV8 prototype. (GenBank accession number: U93872) 
2.2.4.2 Optimisation of HHV8 OFR 26 PCR 
The optimal conditions of HHV8 ORF26 PCR were determined through 
titration of primer concentrations and annealing temperatures. All other PCR 
parameters including the concentration of dNTP and MgC^ and pH value were kept 
constant. In both outer and inner PCR, optimisation of annealing temperature at 
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53°C, 55°C, and 57°C were tried. A series of dilutions of positive controls containing 
DNA equivalent to 25, 2.5, 0.25, and 0.025 BCBL-1 cells per five microlitres was 
used as inoculum for optimisation of outer PGR. For inner PGR, a series of dilutions 
of positive controls containing DNA equivalent to 25, 2.5, 0.25 BCBL-1 cells per 
five microlitres was used as inoculum. 
Primer concentrations ranging from 0.0625 |liM, 0.125 |LiM, 0.25 |jM and 0.50 
|uM were tried for both outer and inner PGR. A series of dilution of positive control 
containing DNA equivalent to 250, 25, 2.5，0.25, and 0.025 BCBL-1 cells per five 
microlitres was used as inoculum. A series of dilutions of positive control containing 
DNA equivalent to 2500, 250, 25, 2.5 and 0.25 BCBL-1 cells per five microlitres 
were used as inoculum for optimisation of inner PGR. 
2.2.4.3 Conditions for HHV8 ORF 26 PCR 
PGR for HHV8 ORF 26 was performed in a 50 |LIL of reaction reagent 
containing Tris-HCL (pH 8.7), (NH4)2S04，KCL, 1.5 mM MgCb, 200 |LLM of each 
clNTP , 0.25 |LIM of outer PCR primer or inner PCR primer, and 1.25 Unit of Hotstar 
Tciq DNA polymerase (QIAGEN, Germany). Preparation of PCR reagent was carried 
out in the clean cabinet available only for the reagent preparation. DNA samples 
were mixed and microcentrifuged briefly before inoculation. Five microlitres of 
supernatant was inoculated into the 45 |iL of PCR master mixture. Thermal cycling 
was done using Applied Biosystem GeneAmp®PCR system 9700. PCR was started 
with initial incubation step at 95°C for 15 min for activation of the Hotstart Tag 
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DNA polymerase. The activation of Hotstar Tag Polymerase was followed by 
denaturing at 94°C for one minute, annealing for one minute and extending at 
for one minute. After 35 cycles, DNA was subjected to an extra extension step that 
lasted for eight minutes at 72°C. For outer PGR, a temperature of 5TC was used as 
annealing temperature. For inner PCR, an annealing temperature of 55°C was used. 
2.2.4.4 Control for PCR contamination 
Particular care was taken to avoid the PCR contamination. PCR master mixture 
was prepared in a clean cabinet only used for reagent preparation. The inoculation of 
original specimen was carried out in a clean space separated from the post-PCR 
procedures. Separate rooms were used for PCR amplification, inoculation of outer 
PCR product and gel electrophoresis. To avoid cross contamination, the apparatus 
and equipments were not allowed to be moved from room to room and gloves were 
frequently changed during the PCR process. 
PCR contamination was also monitored by the negative controls and reagent 
controls. For outer PCR, one negative control from B95 cell lysate and one reagent 
control were included. Double distilled water was used as blank sample control 
between every 10 specimens. For inner PCR, the outer PCR products of B95 cell 
lysate were used as DNA template negative controls. Water control in outer PCR 
was transferred into inner PCR as blank sample control. Reagent control was also 
included in the inner PCR. 
2.2.4.5 Detection of HHV8 ORF 26 PCR product 
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Amplified DNA was size-fractionated by 2% agarose gel. Ten microlitres of 
PGR product were mixed with two microlitres of loading dye (Invitrogen, USA). 
First or second well in upper and lower lines were used for standard DNA mass 
ladder, OX 174 RF DNA/Hae III fragments (Amersham, USA). The inner PGR 
product and PGR controls for both outer and inner PGR were loaded into 
accommodate wells. Electrophoresis was carried out at 120 volt for 60 minutes. The 
gel was stained by ethidium bromide (10 mg/mL) for 10 minutes and was recorded 
by Image Master Video Documentation System (Amersham, USA). A band located 
at DNA size of 160 bp was considered as positive for HHV8 ORF26 nested PGR. 
2.2.5 Statistical methods 
Chi-square test and Fisher's exact test were used to compare the difference in 
DNA prevalence between groups. Risk of HHV8 infection was estimated by 
calculating the odds ratio using Epilnfo 2000 (CDC, USA). All statistical analyses 
were two-tailed. A P value of less than 0.05 was considered significant. 
2.3 Study III. HHV8 ORF 26 nucleotide sequence 
determination 
2.3.1. Study samples 
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Specimens positive for HHV8 DNA by the HHV8 ORF 26 nested PCR were 
amplified by another set of PCR. This PCR set utilized the same primers, KS1/KS2, 
NS1/NS2, and the same PCR conditions except that another DNA polymerase (Bio-
X-ACT DNA polymerase, Bioline, UK), which provided proofreading activity, was 
used. Among 24 cervical scrapes that were positive for HHV8 DNA, nine were 
available for DNA sequence. The remaining samples were not used since the PCR 
product obtained was not sufficient for sequencing. Kaposi's sarcoma tissue samples 
from Chinese non-HIV Kaposi's sarcoma patients were also included in this part of 
study. BCBL-1 cell line was served as a control strain in this study. In order to 
confirm the sequence data, independent PCR amplification had been performed on 
six specimens that were randomly chosen from the nine cervical scrapes and four 
Kaposi's sarcoma tissue samples. 
2.3.2 Sequencing method 
2.3.2.1 Purification of PCR product 
PCR products were purified by MicroSpin™ S-400 HR columns (Amersham, 
USA). Before purification, the resin was resuspended by vortexing the column 
thoroughly and gently. The bottom closure of the column was removed and the 
column was spun at 720 g for one minute. After removal of the flow-through formed 
in the spin, PCR products were applied to the top centre of the resin and the column 
was centrifuged at 720 g for another two minutes. Purified PCR product was 
collected in the bottom of the support tube. The PCR products were subjected to gel 
electrophoresis to access the amount of DNA available for sequencing reaction. 
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2.3.2.2 Direct cycle sequencing 
Cycle sequencing reaction was performed on the purified PCR products with the 
use of ABI Prism® BigDyeT^ Terminator cycle sequencing ready reaction kit v2.0 
(Applied Biosystem, Foster City, USA). HHV8 ORF26 inner primers, NSl and NS2, 
were used as the sequencing primers. Both strands of each product were 
independently sequenced. For each sequencing reaction, eight microlitres of 
terminator ready reaction mix (BigDye teminator, dNTP, MgCb, Tris-HCl buffer 
pH9.0’ AmpliTaq DNA Polymerase), one microlitre of sequencing primer (10 
pi-nol/|LiL) and 11 |liL of template were added. Thirty cycles were used in cycle 
sequencing, which included 10 seconds' denaturation at 96°C, five seconds' 
annealing at 5 TC and four minutes' extension at 60�C. Afterwards, the sequencing 
products were immediately kept at 4°C for further analysis. 
2.3.2.3 Purification of cycle sequencing product 
In order to remove excess dye-labelled dideoxynucleotides and primers 
generated in the cycle sequencing reaction, cycle sequencing products were 
subjected to purification by using AutoSeq'^'^G-50 spin column (Amersham 
Bioscience, USA). After resuspending the resin by vortexing the column, the bottom 
closure was removed and the column was centrifuged at 1960 g for one minute. 
Then, the cycle sequencing product was applied to the centre of the angle surface of 
the compacted resin bed and the column was centrifuged at 1960 g for another one 
minute. The purified product was collected in the bottom of the support tube. After 
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transferring to the centrifuge tube, the products were dried by a vacuum machine 
(Savant, USA) and were resuspended with three microlitres of loading buffer. 
2.3.2.4 Electrophoresis 
2.3.2.4.1 Preparation of glass plates 
Before use, the plates and spacers were rinsed with deionized water, and then 
70% alcohol, and were meticulously wiped by pads of Kimwipes. After that, the 
spacer was arranged in place along each side of the long glass plate. Then, the short 
plate was placed on the long glass plate with the spacers remaining in position at the 
very edges of the two plates. Afterwards, the plates were fixed in a gel cassette and 
the bottom of the plates was bound with gel-sealing tape to make a water-tight seal. 
2.3.2.4.2 Preparation of sequencing gel 
Sequencing gel solution was prepared with 18 g of urea (United States 
Biochemical, USA), five microlitres of long ranger gel solution (FMC Bioprodiict, 
USA), and five microlitres of 10 x TBE. Double distilled water was added to the 
solution to make up the volume to 50 mL. The solution was heated in a 55 °C water 
bath for three minutes to allow dissolution of the urea. After the solution was 
degassed for five minutes, 220 |LLL of 10% ammonium persulfate (Sigma, USA) and 
20 \xL of Tetramethylethylene-Diamine N,N,N',N' (Merck, USA) was added to the 
solution. Afterwards, the gel solution was drawn by a 60-mL hypodermic syringe, 
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and was slowly injected into the hole on the bottom of the gel mold. The flat side of 
shark tooth comb was immediately inserted into the gel solution with an equal depth 
so that the flat surface was formed when the gel was standing in a vertical position. 
2.3.2.4.3 Electrophoresis on DNA sequencer 
After polymerisation of the sequencing gel solution, the gel plates were wiped 
again to remove any dried urea sticking on the plates and the shark tooth comb was 
taken away from gel mold. Afterwards, the gel mold was attached to the ABI Prism 
377 DNA sequencer (Applied Biosystem, Foster City, USA) with the upper and 
lower buffer reservoirs filled with Ix TBE. The gel was run at 2.42 kilovolt for about 
45 minutes to let the temperature of gel reach 51°C. After the pre-run of the gel, 
shark tooth comb was gently inserted into the gel with downward teeth and the comb 
was pushed until the points of the teeth just penetrated the surface of gel. Before 
loading the sample, cycle sequencing product was denatured at 95°C for five minutes 
and chilled on ice immediately. One and half microlitres of sample were injected into 
appropriate slot of the gel. The gel was run at 2.42 kilovolt for five hours. 
2.3.3 Nucleotide sequence data analysis 
Nucleotide sequence substitutions and the predicted amino acid changes were 
analysed with the use of SIMONIC software. HHV8 prototype (GenBank accession 
number: U18551) was used as reference for nucleotide sequence comparison and 
position numbering. To access the genetic relationship between HHV8 isolates 
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generated, phylogenetic tree was constructed by the Clustal W program obtained 








3.1 Study I. Seroprevalence of HHV8 in Hong Kong 
populations 
3.1.1 Seroprevalence of HHV8 in reference group 
A total of 1000 Hong Kong subjects aged from 1 year to 94 years (mean 24.3 ； SD 
19.91) were screened for antibodies against HHV8 latent antigens and lytic antigens. 
Figure 1 shows the positive reactions for antibodies against HHV8 latent and lytic 
antigens. Immunofluorescence for latent antigens showed intranuclear apple green 
signal, while immunofluorescence for lytic antigens showed diffusing cytoplasmic 
apple green signal. Eighty-nine (8.9%) subjects were positive for antibodies against 
HHV8 latent antigens and 21 (2.1%) subjects were tested to have antibodies against 
HHV8 lytic antigens. With the combination of two antibodies, 94 (9.4%) subjects had at 
least one of the two HHV8 antibodies. Table 5 shows the age and sex distribution of 
antibodies against HHV8 latent antigens, antibodies against HHV8 lytic antigens, and 
combination of the two antibodies in this general population group. 
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Figure 1. Immunofluorescence staining of HHV8 latent and lytic antigens 
(A) HHV8 latent antigens indicated by intranuclear apple green signals 
(B) HHV8 lytic antigens indicated by diffused intracytoplasmic apple 
green signals 
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Table 5. Age and sex distribution of HHV8 seroprevalence among the 
general population in Hong Kong 
No. Positive / No. test (%) 
Sex Age Latent Lytic Combined 
Male l-6m 4/50(8%) 0/50 4/50(8 %) 
7-12m 0/50 0/50 0/50 
I-5y 0/50 0/50 0/50 
6-lOy 0/50 0/50 0/50 
II-15y 8/50(16%) 1/50 (2%) 8/50(16%) 
16-20y 3/50 (6%) 0/50 3/50(6%) 
21-30y 5/50(10%) 0/50 5/50(10%) 
31-40y 5/50(10%) 0/50 5/50(10%) 
41-50y 5/50(10%) 0/50 5/50(10%) 
>50y 5/50(10%) 1/50 (2%) 6/50(12%) 
Subtotal 35/500 (7%) 2/500 (0.4%) 36/500 (7.2%) 
Female l-6m 0/50 0/50 0/50 
7-12m 0/50 0/50 0/50 
I-5y 2/50 (4%) 0/50 2/50 (4%) 
6-lOy 6/50(12%) 1/50 (2%) 6/50(12%) 
II-15y 5/50(10%) 4/50 (8%) 5/50(10%) 
16-20y 4/50(8%) 3/50(6%) 6/50(12%) 
21-30y 13/50 (26%) 2/50(4%) 13/50 (26%) 
31-40y 7/50(14%) 1/50 (2%) 8/50(16%) 
41-50y 9/50(18%) 6/50(12%) 10/50 (20%) 
>50y 8/50(16%) 2/50 (4%) 8/50(16%) 
Subtotal 54/500(10.8%) 19/500 (3.8%) 58/500(11.6%) 
Total 89/1000 (8.9%) 21/1000 (2.1%) 94/1000 (9.4%) 
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3.1.1.1 Age distribution 
The HHV8 seropositivity in different age groups is shown in Figure 2. With regard 
to the age distribution of antibodies against HHV8 latent antigens, the seropositivity 
started to rise at six to 10 years, and peaked at the age of 21 to 30 years. The positive 
rates for subjects aged 31 years or above were between 12%-14%. 
As for seropositivity of antibodies against HHV8 lytic antigens, the prevalence rate 
started to increase in children aged 11-15 years, and then declined slowly. A second 
peak at 41-50 years was observed. With the combination of two antibodies, a rising 
trend of HHV8 seroprevalence starting from six to 10 years old followed by a peak at 
age of 21 to 30 years was observed. 




16.0% - T ^ 
14.0% — — T / — T—： 
12.® K ： — ^ " H a t 印 t 
10.® / lytic 
8.0% - f ^ 4“ccOTbined 
6.0% ^ ； 
^ — 
0.(1 ‘ ^ ‘ ‘ 
1-6111 7-12m l-5y 6-lOy ll-15y 16-20y 21-30y 31-40y 41-50y >50y 
Age group 
5 5 
3.1.1.2 Sex distribution 
Altogether, 54 females and 35 males had antibodies against HHV8 latent antigens. 
By Chi-square test, females were found to have a significantly higher positive rate than 
males (P = 0.039’ odds ratio = 1.57, 95% CI = 1.00-2.49). 
As for the antibodies against HHV8 lytic antigens, two males and 19 females were 
positive. By Chi-square test, females were also found to have a significantly higher 
seropositive rate of anbodies against HHV8 lytic antigens than males (P < 0.001, odds 
ratio = 9.66，95% CI = 2.17-60.17). 
With the use of combination of two antibodies tests, 58 females and 36 males were 
found to have at least one of the HHV8 antibodies. By Chi-square test, females also had 
a significantly higher rate of HHV8 infection than males (P = 0.002, odds ratio = 1.65, 
95% CI = 1.06-2.58). 
3.1.2 HIV-negative intravenous drug users 
Sixty-seven HIV-negative intravenous drug users aged from 16 to 50 years were 
included in this group (mean 25.2; SD 8.26). Table 6 shows the comparison of 
seropositivity between this group and age-matched reference group. Three HIV-
negative intravenous drug users (4.4%) including two males and one female were tested 
to have antibodies against HHV8 latent antigens. Seropositivity was statistically 
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significantly lower in this group than the reference group aged from 21 to 30 years by 
Chi-square test (P = 0.010, odds ratio = 0.21, 95% CI = 0.05-0.82). 
For antibodies against HHV8 lytic antigens, four persons including three males and 
one female were found positive. By Fisher's exact test, no significant difference in 
seropositivity existed between this group and the reference group aged 21 to 30 years 
old (P = 0.220, odds ratio = 3.11, 95% CI = 0.47-25.28). 
When the combined results of two antibodies tests were considered, five 
individuals including four males and one female were positive for at least one of the 
antibodies. In comparison to the reference group aged 21 to 30 years, no difference in 
seropositivity existed between them according to Chi-square test (P = 0.052, odds ratio 
=0.37, 95% CI = 0.11-1.13). 
Table 6. Seroprevalence of HHV8 among HIV-negative intravenous drug users in 
comparison with the age-matched reference group 
No. positive (%) 
Study populations No. Tested Latent Lytic Combined 
Intravenous drug users 67 3 (4.4%) 4 (5.9%) 5 (7.4%) 
Reference .group 100 18(18.0%) 2 (2.0%) 18(18.0%) 
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Because among the 67 HIV-negative intravenous drug users, 64 of them are male 
subjects. We used seropositivity of age-matched male subjects (21-30y) to compare 
with this drug users groups (Table 7). For antibodies to HHV8 latent antigens, no 
difference in seropositivity existed between this group and the sex- and age- matched 
reference group according to Fisher's exact test (P = 0.237, odds ratio = 0.29, 95% CI = 
0.04-1.80). For antibodies to HHV8 lytic antigens, since number is too few in one of the 
cell, statistic analysis was not applicable. For a combination of two antibodies tests, 
with the use of Fisher's exact test, no difference in seropositivity existed between this 
group and the sex- and age- matched reference group between 21 to 30 years old (P = 
0.502, odds ratio = 0.60, 95% CI = 0.13-2.77). 
Table 7. Seroprevalence of HHV8 among male HIV-negative intravenous drug 
users in comparison with the sex- and age-matched reference group 
No. positive (%) 
Study populations No. Tested Latent Lytic Combined 
Intravenous drug users(male) 64 2(3 .1 %) 3 (4.7%) 4 (6.3%) 
Reference group 50 5 (5.0%) 0(0%) 5 (5.0%) 
3.1.3 HIV-positive individuals without Kaposi's sarcoma 
This group consisted of five females and 33 males aged from 25 years to 67 years 
(mean 40.3; SD 9.58). Table 8 shows the comparison of seropositivity between the 
HIV-positive, Kaposi's sarcoma-negative patients and the age-matched reference group. 
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One patient was tested positive for antibodies against HHV8 latent antigens. According 
to Fisher's exact test, no statistically significant difference existed between this group 
and the reference group aged from 31 to 50 years old (P = 0.064，odds ratio = 0.18, 95% 
CI = 0.01-1.32). 
With regard to the detection of antibodies against HHV8 lytic antigens, six patients 
were tested to have antibodies against lytic antigens. No female participant was found to 
have antibodies against HHV8 lytic antigens. When compared with the reference group 
aged 31 to 50 years old, this group had a higher seroprevalence by Fisher's exact test (P 
=0.002, odds ratio = 5.17, 95% CI = 1.43-18.61). 
When the combined results of two antibodies tests were considered, six individuals 
were tested to have at least one of antibodies against HHV8 antigens. According to Chi-
square test, no significant difference in HHV8 seroprevalence existed between the HIV-
positive participants and the reference group aged 31 to 50 years old (P = 0.773，odds 
ratio = 1.15, 95% CI = 0.39-3.32). 
Table 8. Seroprevalence of HHV8 among HIV-positive individuals in comparison 
with the age-matched reference group 
No.positive (%) 
Study populations No. Tested Latent Lytic Combined 
Human immunodeficiency 
virus-positive 38 1(2.6%) 6(15.7%) 6(15 .7%) 
Reference group 200 26(13.0%) 7 (3.5%) 28 (14.0%) 
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Because among the 38 HIV-positive individuals, 33 of them are male subjects. We 
used seropositivity of age-matched male subjects (31-50y) to compare with the HIV-
positive individuals (Table 9). For antibodies against HHV8 latent antigens, no 
difference in seropositivity existed between this group and the sex- and age- matched 
reference group according to Fisher's exact test (P = 0.291, odds ratio = 0.28, 95% CI = 
0.01-2.29). For antibodies against HHV8 lytic antigens, since number is too few in one 
of the cell, statistic analysis was not applicable. For a combination of two antibodies 
tests, no difference in seropositivity existed between this group and the sex- and age-
matched reference group according to Fisher's exact test (P = 0.225, odds ratio = 2.00, 
95% CI = 0.58-6.73). 
Table 9. Seroprevalence ofHHVS among male HIV-positive individuals in 
comparison with the sex- and age-matched reference group 
No.positive (%) 
Study populations No. Tested Latent Lytic Combined 
Human immunodeficiency 
virus-positive (male) 33 1(3.0%) 6(18.2%) 6(18.2%) 
Reference group 100 10(10.0%) 0 ( 0 % ) 10(10.0%) 
3.1.4 Transfusion-dependent patients 
This group consisted of 49 transfusion-dependent patients. Their age ranged from 
two to 20 years (mean 11.5, SD 5.05). Table 10 shows the comparison of 
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seroprevalence between this group and the reference group aged six to 15 years. For the 
detection of antibodies against HHV8 latent antigens, four patients including three 
females and one male were positive. There was no difference of seropositivity between 
this group and sex-matched reference group aged from six to 15 years by Fisher's exact 
test (P = 1.000, odds ratio = 0.847，95% CI = 0.27-2.61). 
As for the detection of antibodies against HHV8 lytic antibodies, two patients 
were tested positive, including one female and one male. By Fisher's exact test, there 
was no statistically significant difference in positive rate between this group and the 
sex-matched reference group aged six to 15 years (P = 0.692, odds ratio = 1.17) 
Because of the small size of positive samples, 95% confidence interval was not 
applicable. 
Regarding the combined results of the two antibodies, five transfusion- dependent 
patients including three females and two males had at least one of the HHV8 antibodies. 
By Fisher exact test, no statistically significant difference in HHV8 seropositivity 
existed between this group and the sex- matched reference group aged six to 15 years (P 
=1.000，odds ratio = 1.06, 95% CI = 0.33-3.23). 
Table 10. Seroprevalence of HHV8 among blood transfusion-dependent patients in 
comparison with the sex- and age-matched reference group 
No.positive (%) 
Study populations No. Tested Latent Lytic Combined 
Transfusion dependent 49 4(8 .1%) 2 (4.0%) 5(10 .2%) 
Reference group 200 19(9.5%) 7 (3.5%) 19 (9.5%) 
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3.2 Study II. Prevalence of HHV8 DNA in cervical 
samples 
3.2.1 Optimisation of beta-actin PCR 
The annealing temperature optimisation experiments showed that the detection 
limit for 53�C, 55�C, to 5TC was respectively 2.35 ng, 0.235 ng and 2.35 ng of human 
cellular DNA per five-microlitre inoculum (Figure 3). 
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The primer concentration optimisation experiments showed that the detection limit 
for 0.50 |JM, 0.25 |AM, and 0.125 [iM was respectively 2.35 ng, 0.235 ng, 2.35 ng of 
human cellular DNA per five-microlitre inoculum (Figure 4). As a result, annealing 
temperature of 55°C, and primer concentration of 0.25nM were used for subsequent 
experiments. 
3.2.2 Optimisation of HHV ORF 26 PCR 
For the outer PCR, the annealing temperature optimisation experiments showed 
that the detection limit for 53"C, 55°C, and 57°C was similar (Figure 5). The primer 
concentration optimisation experiments showed that the detection limit for 0.50 |iM, 
0.25 |aM, 0.125 pM’ and 0.0625 |JM was all at 0.25 BCBL-1 cell equivalent (Figure 6). 
As a result, a primer concentration of 0.25 [xM was used for subsequent experiments. In 
order to obtain a higher PCR stringency, an annealing temperature of 57�C was used. 
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M 1 2 3 4 5 6 N R 
309 bp 
M 1 2 3 4 5 6 N R 
309 bp 
M 1 2 3 4 5 6 N R 
‘ WKtKMMK^Bi 
Figure 3. Optimisation of annealing temperature for beta-actin PCR 
The annealing temperature used was (A) 53°C (B) 55°C (C) 57°C 
Amplification target: 309-bp fragment of human beta-actin gene 
Lanes: M, marker 0X-174-RF DNA digested by Hae III 
1，235 ng of humna DNA per inoculum 
2, 23.5 ng of human DNA per inoculum 
3’ 2.35 ng of human DNA per inoculum 
4，0.235 ng of human DNA per inoculum 
5’ 0.0235 ng of human DNA per inoculum 
6’ 0.00235 ng of humanDNA per inoculum 
N, negative control 63 
R, reagent control 
M l 2 3 4 5 N R 
309 bp 
M 1 2 3 4 5 N 
309 b p _ 
M 1 2 3 4 5 N R 
Figure 4. Optimisation of primer concentration for beta-actin PCR 
The primer concentration used was (A) 0.50 |JM (B) 0.25 |IM (C) 0.125|JM 
Amplification target: 309-bp fragment of beta-actin gene 
Lanes: M, marker 0X-174-RF DNA digested by Hcie III 
1，23.5 ng of human DNA per inoculum 
2, 2.35 ng of humanDNA per inoculum 
3，0.235 ng of human DNA per inoculum 
4, 0.0235 ng of human DNA per inoculum 
5, 0.00235 ng of human DNA per inoculum 
N, negative control 
R, reagent control 
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233 b p _ ^ ^ ^ ^ H V H ^ H H j l ^ ^ ^ ^ ^ ^ ^ l 
M 1 2 3 4 N R 
B ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
bp——^ 
C M 1 2 3 4 N R 
• I 
Figure 5. Optimisation of annealing temperature for HHV8 ORF 26 outer PCR 
The annealing temperature used was (A) 53�C (B) 55°C (C) 57°C 
Amplification target: 233-bp fragment of HHV8 ORF 26 
Lanes: M, marker 0X-174-RF DNA digested by Hae III 
1，25 BCBL cells equivalent 
2, 2.5 BCBL cells equivalent 
3, 0.25 BCBL cell equivalent 
4，0.025 BCBL cell equivalent 
N, negative control 
R, reagent control 
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Ai Aii 
M 1 2 3 4 5 N 1 2 3 4 5 
233 bp 
Bi Bii 
M 1 2 3 4 5 N 1 2 3 4 5 
bp 
Figure 6. Optimisation of primer concentration for HHV8 ORF 26 outer PCR 
The primer concentration used was (Ai) 0.50 |JM (Aii) 0.25 pM 
(Bi) 0.125 fjM (Bii) 0.0625 |iM 
Amplification target: 233-bp fragment of HHV8 ORF 26 
Lanes: M, marker 0X-174-RF DNA digested by Hue III 
1, 250 BCBL cells equivalent 
2, 25 BCBL cells equivalent 
3’ 2.5 BCBL cells equivalent 
4’ 0.25 BCBL cell equivalent 
5, 0.025 BCBL cell equivalent 
N, negative control 
R, reagent control 
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For the inner PCR, the annealing temperature optimisation experiments showed 
that the detection limit for 53°C, 55°C, and 5TC was similar (Figure 7). The primer 
concentration optimization experiments showed that the detection limit for 0.50 |aM, 
0.25 |UM, 0.125 |LIM, and 0.0625 ^IM was respectively 0.25, 0.25, 2.5 and 2.5 B C B L - 1 
cells equivalent (Figure 8). As a result, annealing temperature of 55�C and primer 
concentration of 0.25 |iM were used for subsequent experiment. 
3.2.3 Analytical sensitivity of HHV8 nested PCR 
The analytical sensitivity of HHV8 nested PCR was determined by serial dilutions 
of BCBL-1 cell lysate containing the HHV8 DNA. For the outer PCR, the analytical 
sensitivity was at 0.25 BCBL-1 cell equivalent. While for the nested PCR, the analytical 
sensitivity was also at the 0.25 BCBL-1 cell equivalent but with a much stronger signal 
intensity (Figure 9). 
3.2.4. General female population 
Altogether, 193 women were recruited for HHV8 ORF26 PCR. All of them 
provided adequate DNA sample as accessed by beta-actin PCR. Figure 10 shows 
some result of the beta-actin PCR. Women in this group were aged from 19 to 68 
years (mean 41.8; SD 11.08). The overall positive rate for HHV8 DNA in this 
general female (well-women) population was 6.7% (13/193). Figure 11 shows the 
some result of HHV8 nested PCR. 
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Ai Aii 
M 1 2 3 N 1 2 3 R 
160 b p — — } 
B 
M 1 2 3 N 
^ S ^ b H H H H H 
H I 
Figure 7. Optimisation of annealing temperature for HHV8 ORF 26 inner PCR 
The annealing temperature used was (Ai) 53°C (Aii) 55°C (B) 57°C 
Ampli f ica t ion target: 160-bp fragment of HHV8 ORF 26 
Lanes: M, marker 0X-174-RF DNA digested by Hue 111 
1, 25 BCBL cells equivalent 
2, 2.5 BCBL cells equivalent 
3, 0.25 BCBL cell equivalent 
N, negative control 
R, reagent control 
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M l 2 3 4 5 N R 1 2 3 4 5 
160 bp _ 
Bi Bii 
M 1 2 3 4 5 N R 1 2 3 4 5 
160 bp 
Figure 8. Optimisation of primer concentration for HHV8 ORF 26 inner PCR 
The primer concentration used was (Ai) 0.50 |_iM (Aii) 0.25 |JM 
(Bi) 0.125 |JM (Bii) 0.0625 |JM 
Amplification target: 160-bp fragment of HHV8 ORF 26 
Lanes: M, marker 0X-174-RF DNA digested by Hae HI 
1，2500 BCBL cells equivalent 
2, 250 BCBL cells equivalent 
3, 25 BCBL cells equivalent 
4，2.5 BCBL cells equivalent 
5, 0.25 BCBL cell equivalent 
N, negative control 
R, reagent control 
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A 
M 1 2 3 4 5 N R 
2 3 3 b p _ ^ ^ ^ ^ ^ j ^ J H ^ ^ ^ P ^ ^ m i l 
H H B H 
Mmm B 
M 1 2 3 4 5 N R 
Figure 9. Analytical sensitivity of HHV8 nested PCR 
(A) HHV8 outer PCR (B) HHV8 nested PCR 
Amplification target: 233-bp fragment amplified of HHV8 ORF 26 
160-bp fragment amplified by HHV8 ORF 26 
Lanes: M, marker 0X-174-RF DNA digested by Hae III 
1, 25 BCBL cells equivalent 
2, 2.5 BCBL cells equivalent 
3’ 0.25 BCBL cell equivalent 
4’ 0.025 BCBL cell equivalent 
5, 0.0025 BCBL cell equivalent 
N, negative control 
R, reagent control 
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M 1 2 3 4 5 6 7 8 9 10 N 1112 13 14 15 16 17 18 
19 M 20 N 21 22 23 24 25 26 27 28 29 30 31 P R 
A 
Figure 10. Beta-actin PCR for cervical scrape specimens from the well-women group 
Amplification target: 309-bp fragment of human beta-actin gene 
Lanes: M, marker 0 X - 1 7 4 - R F DNA digested by Hae III 
1-31’ cervical scrape sample study subjects 
N, negative control 
P, positive control 
R, reagent control 
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M 1 2 3 4 5 6 7 8 9 10 N 11 12 13 14 15 16 
160 bp 
Figure 11. HHV8 ORF 26 gene PCR for cervical scrape specimens from well-women group 
Amplification target: 160-bp fragment of HHV8 ORF 26 
Lanes: M, marker 0X-174-RF DNA digested by Hae III 
1-10，cervical scrape sample from study subjects 
N, negative control (inner PCR) 
11 ’ positive control (inner PCR) 
12’ B95 cell control (inner PCR) 
13’ reagent control (inner PCR) 
14’ positive control (outer PCR) 
15, B95 cell control (outer PCR) 
16, reagent control (outer PCR) 
72 
3.2.5 Sexually transmitted disease clinic attendees 
Altogether, 202 cervical scrapes were obtained and all had adequate cellular DNA 
samples as indicated by a positive result of beta-actin PCR. Figure 12 shows some result 
of beta-actin PCR. These 202 female sexually transmitted disease (STD) clinic 
attendees were aged from 15 to 66 years (mean 34.4 ； SD 9.70). Figure 13 shows some 
result of the HHV8 nested PCR. The overall HHV8 DNA positive rate was 5.4% 
(11/202). A comparison of HHV8 positive rate by Fisher's exact test showed that no 
statistically difference existed between well women group and the STD clinic attendees 
(P = 0.592, odds ratio = 0.80，95% CI = 0.32-1.95). 
Among the 202 STD clinic attendees, 111 of them reported to have two or more 
sexual partners over the last 12 months, and the remaining 91 persons reported to have 
only one sexual partner over the last 12 months. The HHV8 DNA positive rate in those 
had one sexual partner was 5.49% (5/91). For those reported to have two or more sexual 
partners, the positive rate was 5.41% (6/111). By Fisher's exact test, no significant 
difference on positive rate existed between women who had one sexual partner and 
women who had two or more sexual partners (P = 1.000, odds ratio = 0.98’ 95% CI = 
0.25-3.87). 
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M 1 2 3 4 5 6 7 8 9 10 N 1112 13 14 15 16 17 18 
19 M 20 N 21 22 23 24 25 26 27 28 29 30 N P R 
309 bp _ 
Figure 12. Beta-actin PCR for cervical scrape specimens from sexually 
transmitted disease clinic attendees 
Amplification target: 309-bp fragment of human beta-actin gene 
Lanes: M, marker 0X-174-RF DNA digested by Hae III 
1-30, cervical scrape sample from study subjects 
N, negative control 
P, positive control 
R, reagent control 
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M 1 2 3 4 5 6 7 8 9 10 11 12 
bp ^ 
Figure 13. HHV8 ORF 26 gene PCR for cervical scrape specimens from sexually transmitted 
disease clinic attendees 
Amplification target: 160-bp fragment amplified by HHV8 nested PCR 
Lanes: M, marker marker 0X-174-RF DNA digested by Hae III 
1-5，cervical scrape sample from study subjects 
6, negative control (outer PCR) 
7，negative control(inner PCR) 
8’ positive control (inner PCR) 
9, B95 cell control (inner PCR) 
10’ reagent control (inner PCR) 
11，positive control (outer PCR) 
12’ B95 cell control (outer PCR) 
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3.3 Study III. Sequence variation of HHV8 ORF 26 fragment 
Altogether, 24 HHV8-positive cervical samples were subjected to amplification for 
nucleotide sequence analysis. Nine of them showed amplicon intensity strong enough 
for sequencing reaction. Besides, four Kaposi's sarcoma tissue samples positive for 
HHV8 ORF 26 PCR were also included in sequencing study. BCBL-1 cells were 
included as well. Figure 14 shows purified HHV8 ORF 26 PCR products for sequence 
reaction. The HHV8 prototype (GenBank accession number: U18551)，isolated from a 
United States AIDS-associated Kaposi's sarcoma patients, was used as reference for 
comparison and nucleotide position numbering (Chang et al. 1994). 
The nucleotide sequence variations and predicted amino acid substitutions of the 
nine isolates derived from cervical samples, four Kaposi's sarcoma tissues from non-
HIV subjects, and the BCBL-1 cell lines are shown in Figure 15 and 16. Altogether, six 
nucleotide positions exhibited sequence variations were found over the 120-bp ORF 26 
fragment. The overall nucleotide variability was 5%. The number of nucleotide 
sequence variation for any isolates was ranging from one to five. Of the 13 isolates, 
seven isolates showed more than one nucleotide sequence variation over the 120-bp 
region. Six isolates showed only one nucleotide variation. 
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M 1 2 3 4 5 6 7 
8 M 9 10 11 12 13 14 
Figure 14. Purified HHV8 ORF 26 PCR product for sequencing analysis 
Amplification target: 160-bp fragment of HHV8 ORF 26 
Lanes: M, marker 0X-174-RF DNA digested by Hae III 


























































































































































































































































































































































































































































































































































































































































































































































































































































Among the six observed nucleotide substitutions, nt 1055, 1086 and 1139 were 
synonymous whereas the other nucleotide variations at nt 1108 and 1132 were 
nonsynonymous. At nt 1108, serine (S) was changed to tyrosine (Y). At nt 1132, 
aspartic acid (D) was changed to glycine (G). Regarding nt 1103, a nucleotide 
substitution from "C" to "A" did not result in amino acid substitution. However, 
nucleotide substitution from "C" to "G" at the same position resulted in changing of 
amino acid from isoleucine (I) to methionine (M). Overall, all the 13 isolates had 
nucleotide substitutions whereas five of them exhibited amino acid changes. 
The isolates were classified into subtype A, B, and C based on the system proposed 
by Zong et al. (Zong, Metroka and Reize 1997). Three nucleotide positions at nt 1086, 
1132, 1139 were considered key subtype indicators. Under this scheme, the HHV8 
prototype (U18551) represented HHV8 subtype A pattern. HHV8 subtype B strain was 
determined by the nucleotide variation from "A" to "G" at nt 1132. A substitution from 
nucleotide "C" to "T" at nt 1086 is an indicator for subtype C. Accordingly, six cervical 
isolates were classified as subtype A strains, three cervical isolates were classified as 
subtype B strains. Table 11 shows the genotyping of the 13 isolates and one BCBL-1 
cell line. Regarding the isolates from Kaposi's sarcoma tissues, two of them were 
classified into subtype B and the other two strains fell into subtype C. 
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Table 11. Genotypes and nucleotide substitutions of HHV8 ORF 26 among BCBL-1 
cell line, Kaposi's sarcoma samples, and cervical samples 
Strain ORF 26~120(bp) Subtype 
1055 1086* 1103 1108 1132* 1139* 
Reference strain G C C C A A A 
BCBL-1 cell line G C C C A A A 
Cervical samples 
ST49 G C A C A A A 
ST73 G C A C A A A 
ST 123 G C A C A A A 
ST145 T C C C G C B 
9707 T C C C G C B 
9744 T C G A G C B 
10589 G C A C A A A 
10169 G C A C A A A 
10191 G C A C A A A 
Kaposi's sarcoma 
KSl T C C C G C B 
KS2 T C C C G C B 
KS3 G T C C A C C 
KS4 G T C C A C C 
* the subtype indicator loci recommended by Zong et al. (Zong, Metroka et al. 1997) 
Reference strain: HHV8 prototype (GenBank accession number: U18551) 
The ORF 26 nucleotide sequences of the nine isolates from cervical samples, four 
isolates from Kaposi's sarcoma tissues and one BCBL-1 cell line were compared with 
13 other HHV8 sequences obtained from GenBank or published literature (Cesarman, 
Moore and Rao 1995). These 13 published ORF 26 nucleotide sequence were obtained 
from United States (U18551, KSU61122, KSU61130, AF042147, AF042148), Africa 
(KSU61117, AY042996, AY042999, KSU61136), France (AF042371), Korea 
(AF101484), Japan (S83360), respectively and the nucleotide sequence data of BCBL-1 
8 1 
cell line was from published literature (Cesarman, Moore and Rao 1995). Figure 17 
shows the phylogenetic tree constructed from the 27 HHV8 ORF 26 sequences 
generated from our study and those derived from GenBank or literatures. Since we used 
cladogram to describe the phylogenetic relationship between these sequence data, the 




































































































































































































































































































































































































































































4.1 study I. Seroprevalence of HHV8 in Hong Kong 
populations 
HHV8 is the first gamma-II herpesvirus known to be infectious to human. 
Understanding the seroepidemiology is critical to determine the transmission modes 
and its associated risk factors for infection. 
In this study, antibodies against HHV8 latent antigens and antibodies against 
lytic antigens have been tested. Our results show that seropositivity measured by 
antibodies against HHV8 latent antigens is higher than that measured by antibodies 
against HHV8 lytic antigens. Although some studies reported that IFA-lytic assay 
was more sensitive than IFA-latent assay in determining HHV8 infection in Kaposi's 
sarcoma patients and HIV-positive, Kaposi's sarcoma-negative homosexual men, 
there is little information about the comparison of these two assays in investigating 
the HHV8 seroprevalence in the general population. In our study, we used treated 
BCBL-1 cells as source of lytic antigens and cells were harvested 96 hours' lytic 
induction by chemicals. However, whether the lytic antigens were expressed in most 
BCBL-1 cells in an antigen smear was uncertain. This might cause the low 
sensitivity of lytic antibodies test in our study. On the other hand, whether the 
immunofluorescence signal in latent antibodies tests represents the true latent 
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nuclear-associated antigens remains to be determined. Further study should be 
carried out by IFA followed by Western blot assays which are more reliable, sensitive 
and specific in determining the HHV8 seroprevalence. 
Because of a relative poor concordance and low sensitivity of the available 
serologic assays, we used a combination of antibodies against HHV8 latent and lytic 
antigens to estimate the distribution of HHV8 in Hong Kong (Rabkin, Schulz and 
Whitby 1998). 
4.1.1 Distribution of HHV8 in reference group 
Little has been done on the HHV8 seroprevalence in Southern East Asia, where 
another gamma herpesvirus, Epstein-Barr virus, has a high prevalence in these 
populations. This study showed that 9.4% of reference group had either the 
antibodies against HHV8 latent antigens or against HHV8 lytic antigens. This 
percentage rate is in contrast to the high percentage (63.3%) of HHV8 DNA found 
from brain tissues among Hong Kong people as reported by Chan et al. (Chan et al. 
2000). The true explanation for this discrepancy is currently not known. One possible 
reason is that the antibodies detected in the current study lasted only for certain 
period following infection, and may not detect individuals who have been infected in 
the distant past. From our study, the observed low overall HHV8 seroprevalence 
among Hong Kong population is similar to that from United States, Northern Europe 
and Taiwan (Huang et al. 2000) (Blauvelt et al. 1997) (Louise, Chatlynne and 
Ablashi 1999) (Enbom, Sheldon and Lennette 2000). 
Regarding sex distribution, the female population was found to have a higher 
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prevalence of HHV8 antibodies than the male population. Similar observation of 
higher prevalence of HHV8 among women has been reported from Taiwan (Huang et 
al. 2000). However, whether the female population has a higher risk for HHV8 
infection than males remains to be determined, since our results on sex distribution 
are only at marginal significance. Further studies are required to confirm this 
observation. 
As for age distribution, this study showed that HHV8 infection was rare among 
children under 10 years old. The seroprevalence rate started to rise from 11 years and 
peaked at the age group 21 to 30 years old. After that, the seropositivity declined to 
around 14%, and kept at that level among individuals older than 50 years. The age 
distribution of HHV8 observed in this study suggests that most HHV8 infection 
occurs after puberty, which is similar to that found in United States and Taiwan, but 
is different from that reported from Kaposi's sarcoma endemic areas (Gessain et al. 
1998) (Martin, Ganem and Osmond 1998) (Huang et al. 2000). Blauvet and his 
colleagues found that primary infection of HHV8 occurred predominantly in adults, 
which suggest a sexual transmission mode of HHV8 infection in the United States 
(Blauvelt et al. 1997). Our observations that primary infection of HHV8 occurred in 
adulthood suggest that sexual transmission mode of HHV8 infection is likely in 
Hong Kong. However, the non-sexual transmission of HHV8 in Hong Kong may 
also exists because a small proportion of children and early teenagers were also 
positive for HHV8 antibodies. 
4.1.2 HIV-positive individuals without Kaposi's sarcoma 
In this study, HIV-positive individuals were selected to find out whether Hong 
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Kong HIV-positive subjects are at higher risk for HHV8 infection. Our findings show 
that the HHV8 seroprevalence among HIV-positive Hong Kong subjects is low 
(15.7%). The HHV8 seropositivity in this group is similar as that in the sex- and 
age-matched general population. Our observation accords with the findings from 
Southeast Asia where similar seroprevalence rates of HHV8 antibodies were found 
between the age-matched general populations and the HIV-positive individuals 
(Louise, Chatlynne and Ablashi 1999). In addition, this is also in line with the fact 
that Kaposi's sarcoma rarely occurs among the AIDS patients in Hong Kong and Asia 
(Sukpanichant, Sonakul and Plankijagum 1998). 
4.1.3 HIV-negative intravenous drug users 
HIV-negative intravenous drug users were included in the HHV8 
seroprevalence study in order to investigate whether HHV8 could be transmitted via 
sharing of sheedles. We observed that no significant difference in HHV8 
seropositivity existed between the HIV-negative intravenous drug users and the sex-
and age-matched reference group. Our finding suggests that sharing of needles might 
not be an efficient transmission route of HHV8. This might due to the relative low 
viral copy numbers in plasma as reported by some scientists (LaDuca et al. 1998). 
Our observation also correlates with other findings that HIV-negative intravenous 
drug users may not at a higher risk for HHV8 infection (Rezza, Lennette and Giulani 
1998). 
4.1.4 Transfusion-dependent patients 
HHV8 seroprevalence of transfusion-dependent patients were investigated to 
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determine whether blood transfusion is risk factor for HHV8 infection. In this study, 
transfusion-dependent recipients were not found to have a higher risk of HHV8 
infection than the sex- and age-matched reference group. This is in line with the 
observation that blood product recipients are not at a significant higher risk for HHV8 
infection. (Operskalski, Busch and Mosley 1997). Furthermore, other studies 
showed that HHV8 DNA sequence was not detectable in patients who had received a 
large number of blood components during their lives (Lefrere, Mariotti and Girot 
1997). However, our observation of no difference in HHV8 antibody positive rate 
cannot exclude the possibility of transmission of the virus through blood transfusion, 
since around 10% of transfusion-dependent patients were detected to have HHV8 
antibodies. Large-scale screening of blood donors and recipients is required to get a 
better estimate of the risk of transmission of HHV8 via transfusion. 
4.2 Study II. Prevalence of HHV8 DNA in cervical samples 
Epidemiological studies have identified that promiscuity, HIV-seropositivity 
and a history of sexually transmitted diseases are associated with an increased 
seroprevalence for HHV8 (Melbye et al. 1998) (Martin, Ganem and Osmon 1998) 
(O'Brien et al. 1999). However, the route of HHV8 acquisition still remains to be 
determined. Some reported that HHV8 DNA was detectable in genital tract and in 
semen from Kaposi's sarcoma patients, pointing out the likehood of sexual 
transmission of the virus ( LaDuca et al. 1998) (Diamond et al. 1997). However, 
Enbom et al. found that HHV8 DNA was not detectable from the cervical samples 
from healthy Swedish women (Enbom et al. 2001). In order to find out whether 
HHV8 could be transmitted via the genital tract, we investigated HHV8 DNA 
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prevalence in cervical scrapes from the general female population as well as the 
sexually transmitted diseases clinic attendees in Hong Kong. 
4.2.1 General female population 
In this study, the HHV8 DNA prevalence in general female population was 
tested and was used as baseline in comparison with the DNA prevalence in sexually 
transmitted disease clinic attendees. HHV8 DNA was detected in 13 out of 193 (6.7%) 
cervical scrape samples from the general female population. This was compatible 
with the observation that HHV8 DNA was detectable from 35 out of 404 (8.7%) 
cervical cell samples from women attending colposcopy clinic for abnormal cervical 
smears (Chan et al. 1999). Our current findings and the previous report from Chan et 
al. suggest that the genital tract secretion could be a possible source for sexual or 
vertical transmission of HHV8 infection. 
4.2.2 Sexually transmitted disease clinic attendees 
The sexually transmitted disease clinic attendees were included in the DNA 
prevalence study to find out whether HHV8 infection was associated with a history of 
sexually transmitted diseases. In our study, HHV8 DNA was found in 11 out of 201 
(5.4%) sexually transmitted disease clinic attendees. Similar HHV8 infection rate has 
been observed among those with one sexual partner and those with two or more 
partners. This suggested that HHV8 infection might not be efficiently transmitted by 
genital tract contact. 
Although our current study does not reveal a difference in cervical carriage rate 
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for HHV8 DNA between the sexually transmitted disease clinic attendees and the 
well-women group, this does not necessarily exclude sexual promiscuity as a risk 
factor for HHV8 infection. It might due to the transient shedding of HHV8 DNA in 
cervical secretion. Unfortunately, we did not have a chance to study the 
seroprevalence of the sexual promiscuous group that would be valuable to further 
elucidate this point. 
4.3 Study III. HHV8 ORF 26 nucleotide sequence variation 
4.3.1 Sequence variability 
We examined a 120-bp DNA fragment from 13 HHV8 ORF 26 positive isolates 
and discovered six nucleotide variation positions. Among these, nucleotide 
substitutions at nt 1055, 1086, 1132, and 1139 had been reported in previous studies 
(Zong, Metroka and Reize 1997) (Chang et al. 1994), whereas nucleotide variations at 
nt 1103 and nt 1108 had not been reported before. 
4.3.2 HHV8 ORF26 genotyping 
By studying the 120-bp fragment of ORF 26, we found that all the analysed 
isolates belong to A, B, or C subtype according to the classification of HHV8 
variants proposed by Zong et al. (Zong, Metroka and Reize 1997). Subtype A strains 
comprised of six cervical isolates. Subtype B strains comprised of three cervical 
isolates and two isolates from Kaposi's sarcoma tissues. Subtype C strains consisted 
of two Kaposi's sarcoma isolates. In our study, subtype A and B were the main 
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subtypes found among cervical samples. This distribution pattern is similar to that of 
United States where subtypes A and B are predominant in HIV-positive patients 
without Kaposi's sarcoma. However, among isolates from Kaposi's sarcoma tissues, 
none of them belonged to subtype A. This distribution pattern is closer to that 
prevalent in Africa where strains mostly fell either B or C subtype (Zong, Metroka 
and Reize 1997). 
So far little data is available on the comparison of genotypes of HHV8 detected 
from different tissues or cell types. Our data, though based on a small number of 
samples, suggests a clustering of cervical secretion-derived isolates into subtype A 
and subtype B, whereas Kaposi's sarcoma tissue-derived isolates into subtype B and 
C. It would be worthwhile to further investigate whether there is an association 
between genotype and tissue tropism of HHV8. 
4.3.3 Comparison with HHV8 isolates from other populations 
To determine the genetic relationship between our isolates and those 
published by others, phylogenetic tree was contructed based on the 120-bp HHV8 
ORF 26 fragment of 13 Hong Kong isolates, six United States isolates, four African 
isolates, two Asian isolates and one European isolate. In the phylogenetic tree, the 
isolates generated in our study mostly clustered into three groups. The first group 
compiled of all subtype A strains in our study but not any other strain published by 
others. The second group consisted of six strains belonging to subtype B. Of the 
seven isolates, five isolates were from our study and the remaining two strains were 
from Europe and United States. The third group consisted of two strains from 
Karposi's sarcoma in our study and one strain from Uganda, a Kaposi's sarcoma 
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endemic area. 
The phylogenetic comparison with HHV8 isolates derived from other 
populations suggests that most HHV8 isolates derived from Hong Kong belongs to 
the same branch of the phylogenetic tree. Herpesviruses are regarded as relatively 
inert to mutation and the genetic evolution of the viruses of this family takes a much 
longer time. From the model of human papillomavirus, double-stranded DNA virus 
may co-evolve with the host and show a strong association between viral genomic 
sequence variations with ethnicity (Ho et al. 1991). It would be worthwhile to 
investigate whether the genomic sequence variation of HHV8 also behaves in this 
way. 
4.4 Conclusions 
HHV8 is the first gamma-II herpesvirus known to be infectious to human. 
Understanding the viral transmission mode and identifying risk factors for HHV8 
acquisition is critical for further understanding on the clinical impact of this virus. 
By immunofliierescence assay, we found that around 10% of study populations 
had HHV8 antibodies, which indicates the existence of HHV8 infection in Hong 
Kong. Moreover, the age distribution of HHV8 seropositivity in Hong Kong people 
suggests that both sexual and non-sexual transmission of HHV8 exist in Hong Kong. 
Regarding the HIV-positive individuals, our findings supports the viewpoint that 
HIV infection is not always accompanied with a higher risk of HHV8 acquisition. 
We also found that intravenous drug users and transfusion-dependent blood 
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recipients had no significant difference in seropositivity comparing to the sex- and 
age-matched reference groups. However, it does not exclude the transmission of 
HHV8 via blood transfusion and percutaneous route, especially among certain 
populations such as the immunocompromised patients. Further serosurvey on 
HHV8-positive blood donors and their recipients is necessary in determining the risk 
for HHV8 infection via transfusion of blood product. 
With respect to HHV8 DNA detection in cervical scrapes, although a certain 
proportion of HHV8 DNA has been observed in both the general female population 
and the sexually transmitted disease clinic attendees, the similar DNA prevalence in 
these populations suggests that HHV8 might not be efficiently transmitted by genital 
tract secretion. As for the genotyping study, all cervical isolates were classified into 
A or B subtypes, and Kaposi's sarcoma isolates were classified into B or C subtype. 
It would be worthwhile to obtain more sequence data from different populations in 
Hong Kong to elucidate the genotyping association with tissue tropism and 
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